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The International Diabetes Federation estimates that 415 million adults world-
wide now have diabetes and 318 million have impaired glucose tolerance. These
numbers are expected to increase to 642 million and 482 million, respectively, by
2040. This burgeoning pandemic places an enormous burden on countries
worldwide, particularly resource-poor regions. Numerous landmark trials evalu-
ating both intensive lifestyle modification and pharmacological interventions
have persuasively demonstrated that type 2 diabetes can be prevented or its
onset can be delayed in high-risk individuals with impaired glucose tolerance.
However, key challenges remain, including how to scale up such approaches for
widespread translation and implementation, how to select appropriately from
various interventions and tailor them for different populations and settings, and
how to ensure that preventive interventions yield clinically meaningful, cost-
effective outcomes. In June 2015, a Diabetes Care Editors’ Expert Forum convened
to discuss these issues. This article, an outgrowth of the forum, begins with a
summary of seminal prevention trials, followed by a discussion of considerations
for selecting appropriate populations for intervention and the clinical implications
of the various diagnostic criteria for prediabetes. The authors outline knowledge
gaps in need of elucidation and explore a possible new avenue for securing reg-
ulatory approval of a prevention-related indication for metformin, as well as
specific considerations for future pharmacological interventions to delay the on-
set of type 2 diabetes. They conclude with descriptions of some innovative, prag-
matic translational initiatives already under way around the world.
According to the latest International Diabetes Federation (IDF) calculations, an
estimated 415 million adults worldwide (8.8% of the global population) have dia-
betesda number that is projected to increase to 642 million (10.4%) by 2040. The
vast majority of diabetes cases are attributable to type 2 diabetes. Furthermore, an
estimated 318 million adults have impaired glucose tolerance (IGT). That number is
expected to climb to 482 million in the next 25 years (1). In the U.S. alone, an
estimated 86 million adults have prediabetes (2).
The toll of diabetes and its complications on patients’ health and quality of life is
enormous. The burgeoning diabetes pandemic also places a great burden on coun-
tries throughout the world, particularly in resource-poor regions. The IDF estimates
that global spending to treat diabetes ranged between $673 billion and $1.2 trillion
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USD in 2015 (1). A recent global analysis
found that a substantial portion of this
burden falls on patients in low- andmiddle-
income countries as out-of-pocket costs
(3). In concert with the predicted in-
crease in new cases of diabetes, global
expenditures are projected to rise to be-
tween $802 billion and nearly $1.5 tril-
lion USD by 2040 (1).
Diabetes is also a leading cause of
death. High blood glucose has been
identified as the third largest risk factor
for premature mortality worldwide, af-
ter high blood pressure and tobacco use.
Approximately 5 million deaths were at-
tributable to diabetes in 2015dmore
than those from HIV/AIDS, tuberculosis,
and malaria combined (1,4).
Numerous landmark trials in the past
quarter-century have demonstrated
conclusively that preventive strategies
(i.e., lifestyle modification and various
pharmacological interventions) can de-
lay or prevent the development of
type 2 diabetes in high-risk individuals
with IGT (5–22). Despite the clarity of
these findings and large reported effect
sizes, translational prevention programs
have faced numerous real-world imped-
iments, and none of the tested interven-
tions have been widely adopted as
components of routine clinical care.
There are encouraging signs that this
may soon change. An independent expert
panel recently confirmed that the expan-
sion of the National Diabetes Prevention
Program (NDPP) (23), a public-private ini-
tiative funded by the Affordable Care Act
and launched in 2010 to encourage the
provision of evidence-based interven-
tions in communities across the country,
would reduce spending and improve the
quality of patient care (24). This certifica-
tion is a crucial step toward expanding
NDPP for Medicare beneficiaries with
prediabetes.
Despite this encouraging news, key
challenges remain, including identifying
those interventions most suitable for
widespread implementation, selecting
appropriately from and tailoring these
tools for various populations and set-
tings, and measuring the impact of their
implementation on disease progression
and on micro- and macrovascular com-
plications (23,25,26). To consider these
issues, a Diabetes Care Editors’ Expert
Forum was convened in June 2015. Pan-
elists reviewed the prevention evidence
to date, discussed areas of controversy,
identified unanswered research ques-
tions, and explored innovative ap-
proaches to translating this research to
reduce the incidence of type 2 diabetes.
This article summarizes the proceedings
of that forum.We use the term “preven-
tion” throughout the article to refer to
delaying the progression to type 2 dia-
betes in a proportion of a population at
risk. Ascertaining which individuals will
progress from prediabetes to diabetes
(and when) is not possible currently.
Therefore, it is not feasible to demon-
strate that an intervention has pre-
vented the lifelong occurrence of
diabetes in an individual or a population
of individuals who are otherwise certain
to progress. For now, intervention trials
can only determine the fraction of the
studied population that progresses to
diabetes. The number of cases that
have been prevented during a trial can
be derived from positive results, but this
calculation has to be qualified by the
limited observation period and the like-
lihood that treatment must be contin-
ued indefinitely to preserve some or all
of the prevented cases.
TYPE 2 DIABETES PREVENTION
STUDIES: PROGRESS TO DATE
Charting the future of diabetes preven-
tion and suggesting logical next steps
requires a critical review of the key stud-
ies. Different interventions and ap-
proaches carried out in a variety of
settings in diverse populations have
yielded nearly uniform evidence in sup-
port of both lifestyle modification and
pharmacotherapy as viable means for
delaying or preventing diabetes in high-
risk individuals (5–22) (Table 1).
The groundbreaking Da Qing IGT and
Diabetes Study (5) was the first large-
scale prevention trial to test the efficacy
of lifestyle intervention and has pro-
vided the longest follow-up data. It
compared the effects of dietary modifi-
cation, exercise, or both to a control
group given no intervention in high-
risk Chinese adults with IGT. After 6
years, the cumulative incidence of dia-
betes by 1985 World Health Organiza-
tion (WHO) criteria (fasting plasma
glucose [FPG] .140 mg/dL [7.8 mmol/L]
or 2-h postload plasma glucose .200
mg/dL [11.1 mmol/L]) was significantly
reduced by 31–46% in all interven-
tion groups. Evaluation studies involv-
ing 94% of the original cohort at the
20- and 23-year follow-ups (27,28)
showed a durable 43% lower diabetes
incidence rate, a 47% reduction in severe
diabetic retinopathy (29), and, by year 23,
significant reductions in cardiovascular
(41%) and all-cause (29%) mortality.
The Finnish Diabetes Prevention
Study (DPS) (6,30) examined the effects
of lifestyle intervention in middle-aged,
overweight adults with IGT. Participants
were individually randomized to either
an intervention group that received on-
going individualized counseling aimed at
reducing weight, making healthy dietary
modifications, and increasing physical
activity or a control group receiving gen-
eral diet and exercise advice but no in-
dividualized counseling. After 4 years,
diabetes risk was reduced by 58% in
the intervention group, which also had
greater improvements in all parameters
of the metabolic syndrome. No cases of
diabetes developed among people who
reached at least four of the study’s five
lifestyle intervention targets for diet and
physical activity (6). Long-term follow-
up found a sustained relative risk reduc-
tion in diabetes incidence of 43% after
7 years and 38% after 13 years, while the
absolute risk difference between groups
continued to increase through 13 years
(31,32).
The American Diabetes Prevention
Program (DPP) (7) demonstrated that
lifestyle modification and, to a lesser ex-
tent, metformin therapy can reduce the
incidence of diabetes in high-risk indi-
viduals. Overweight adults with IGT
and an FPG .95 mg/dL (5.3 mmol/L)
were randomized to either intensive
lifestyle intervention focusing on weight
loss and exercise, metformin therapy, or
placebo. After a mean 2.8 years, the life-
style intervention reduced the cumula-
tive incidence of diabetes by 58% (a
reduction identical to that noted in the
DPS), and the reduction with metformin
was 31%, compared with placebo. A
fourth DPP arm using the thiazolidine-
dione (TZD) troglitazonewas discontinued
early because of the drug’s hepatotoxic-
ity. After amean 0.9 year of therapy in the
troglitazone arm, diabetes incidence was
reduced by 75% compared with placebo.
However, 3 years after troglitazone with-
drawal, the diabetes incidence rate was
almost identical to that of the placebo
group (33). The DPP lifestyle intervention
also yielded improvements in all tradi-
tional, as well as many nontraditional,
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cardiovascular risk factors (34). In the follow-
up DPP Outcomes Study, cumulative di-
abetes incidence rates still differed
significantly 10 years (34 and 18% for
lifestyle and metformin compared with
placebo, respectively) and 15 years (27
and 17%, respectively) after initial ran-
domization into the DPP (34,35). A pro-
jection of the DPP interventions’ effects
over a lifetime yielded estimates that the
lifestyle and metformin interventions
delayed diabetes by 11 and 3 years, re-
spectively, but also reduced the absolute
incidence of diabetes by 20 and 8%, re-
spectively (36). However, no differences
in aggregate microvascular or cardiovas-
cular outcomes by randomized arm have
become evident in the DPP, although the
expected lower prevalence of microvas-
cular complications in those who did not
develop diabetes was reported (35).
Two Indian Diabetes Prevention Pro-
gramme studies (IDPP-1 and IDPP-2)
(8,9) focused on developing practical,
translatable lifestyle interventions and
contributed important insights regard-
ing potential ethnicity-based variations
in both the pathophysiology of diabetes
and responses to lifestyle and pharma-
cological interventions. In the IDPP-1,
Asian Indian adults with IGTdwho
were younger and leaner than the sub-
jects in the Finnish and American studies
(6–8)dwere assigned to either a sim-
ple lifestyle intervention encouraging
healthy dietary changes and increased
exercise, low-dose metformin therapy
(500 mg daily), a combination of lifestyle
modification plus metformin, or no in-
tervention (control). After 3 years, dia-
betes risk was reduced by 28.5, 26.4,
and 28.2% in the lifestyle, metformin,
and combination groups, respectively.
Both interventions also had positive ef-
fects on LDL cholesterol but not on
blood pressure (37). The IDPP-2 (9)
tested whether adding the TZD pioglita-
zone would enhance the efficacy of the
IDPP-1 lifestyle intervention. In stark
contrast to a 72% diabetes risk reduc-
tion found with pioglitazone in the U.S.
ACT NOW (Actos Now for Prevention of
Diabetes) study (10) (discussed below),
pioglitazone had no significant effect
beyond that of lifestyle intervention in
the IDPP-2 population. The potential
ethnic differences in responses to phar-
macological preventive therapy identi-
fied in these studies require further
investigation. If substantiated, they rep-
resent an important additional issue to
be addressed in any global prevention
strategy.
Table 1—Major type 2 diabetes prevention trials
Location n Intervention Reference
Da Qing IGT and Diabetes Study China 577 Lifestyle modification Pan et al., 1997 (5)
Finnish Diabetes Prevention Study (DPS) Finland 522 Lifestyle modification Tuomilehto et al., 2001 (6)
Diabetes Prevention Program (DPP) U.S. 3,234 Lifestyle modification,
metformin
Diabetes Prevention Program Research
Group, 2002 (7)
Indian Diabetes Prevention
Programme-1 (IDPP-1) India 531
Lifestyle modification,
metformin Ramachandran et al., 2006 (8)
Indian Diabetes Prevention
Programme-2 (IDPP-2) India 407
Lifestyle modification plus
pioglitazone Ramachandran et al., 2009 (9)
Zensharen Study for Prevention of
Lifestyle Diseases Japan 641 Lifestyle modification Saito et al., 2011 (11)
Prevention of type 2 diabetes by
lifestyle intervention Japan 458 Lifestyle modification Kosaka et al., 2005 (12)
TRIPOD (Troglitazone in the Prevention
of Diabetes) U.S. 266 Troglitazone Buchanan et al., 2002 (13)
DREAM (Diabetes Reduction Assessment
with Ramipril and Rosiglitazone
Medication) International 5,269 Rosiglitazone DREAM Trial Investigators, 2006 (14)
ACT NOW (Actos Now for Prevention of
Diabetes) U.S. 602 Pioglitazone DeFronzo et al., 2011 (10)
CANOE (Canadian Normoglycemia
Outcomes Evaluation) Canada 207 Rosiglitazone plus metformin Zinman et al., 2010 (15)
ORIGIN (Outcome Reduction With Initial
Glargine Intervention) International 12,537 Insulin glargine ORIGIN Trial Investigators, 2012 (16)
STOP-NIDDM (Study to Prevent Non-Insulin-
Dependent Diabetes Mellitus) International 1,429 Acarbose Chiasson et al., 2002 (17)
Voglibose for prevention of type 2
diabetes mellitus Japan 1,780 Voglibose Kawamori et al., 2009 (18)
EDIT (Early Diabetes Intervention Trial) U.K. 631 Acarbose, metformin Holman et al., 2000 (19)
NAVIGATOR (Nateglinide and Valsartan in
Impaired Glucose Tolerance Outcomes
Research) International 9,306 Nateglinide, valsartan NAVIGATOR Study Group, 2010 (20)
XENDOS (Xenical in the Prevention of
Diabetes in Obese Subjects) Sweden 3,305 Orlistat Torgerson et al., 2004 (21)
SCALE (Satiety and Clinical
AdipositydLiraglutide Evidence) International 3,731 Liraglutide Pi-Sunyer et al., 2015 (22)
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The Japanese Zensharen Study for
Prevention of Lifestyle Diseases (11)
evaluated overweight Japanese adults
with FPG levels of 100–125 mg/dL
(5.6–6.9 mmol/L) who were randomly
assigned to either a frequent or less fre-
quent (control) lifestyle intervention
program for 3 years. The frequent inter-
vention resulted in an overall 44% re-
duction in diabetes incidence, although
subgroup analyses revealed that it was
effective in participants with combined
impaired fasting glucose (IFG) and IGT
(59% relative risk reduction) or high
baseline A1C (76% relative risk reduc-
tion) but had no effect in those with
isolated IFG or lower baseline A1C. In
another, smaller Japanese lifestyle in-
tervention study, men with IGT were
randomly assigned to a standard inter-
vention group (control) or an intensive
intervention group (12). Subjects in
the control group and in the intensive
intervention group were advised to
maintain a BMI of ,24.0 and ,22.0
kg/m2, respectively, through diet and
exercise. In the intensive group, detailed
instructions on lifestyle modification
were repeated every 3–4 months. The
cumulative 4-year incidence of diabetes
was 9.3% in the control group and 3.0%
in the intensive intervention group; re-
duction in diabetes risk from the inten-
sive intervention was 67.4%.
Because virtually all of the early dia-
betes prevention research suggested
that the success of an intervention lies
partly in its ability to improve insulin
sensitivity and because TZDs were
known to reduce insulin resistance, a
number of studies have examined the
effect of this class of agents. The TRIPOD
(Troglitazone in the Prevention of Dia-
betes) study (13) demonstrated that
troglitazone could reduce the risk of de-
veloping diabetes by 55% in Hispanic
women with a history of gestational di-
abetes mellitus (GDM). The DREAM (Di-
abetes Reduction Assessment with
Ramipril and Rosiglitazone Medication)
trial (14) examined the preventive value
of rosiglitazone, and ACT NOW (10) did
the same with pioglitazone. In the
DREAM trial, adults with IFG (FPG 110
to ,126 mg/dL [6.1 to ,7.0 mmol/L]),
IGT, or both were randomly assigned to
either rosiglitazone 8 mg daily or pla-
cebo. After 3 years, the composite out-
come of incident diabetes or death was
reduced by 60% in the rosiglitazone
group, most of which was due to a re-
duction in incident diabetes. Rosiglita-
zone was also shown to increase the
likelihood of reversion to normal glu-
cose tolerance (NGT) by ;70–80%. In
ACT NOW, overweight adults with IGT
were randomly assigned to either pio-
glitazone titrated to 45 mg daily or
placebo. During a median follow-up
of 2.4 years, the pioglitazone group
had a 72% reduction in diabetes risk
compared with placebo. In addition, the
CANOE (Canadian Normoglycemia Out-
comes Evaluation) trial (15) found that
low-dose combination therapy with rosi-
glitazone 2 mg plus metformin 500 mg
twice daily in adults with IGT reduced the
relative risk of diabetes by 66% during a
median 3.9 years of treatment with sig-
nificantly fewer adverse events than in
the DREAM trial. Longer-term passive
follow-up of the DREAM cohort showed
that at a median 1.6 years after the end
of the trial and 4.3 years after randomi-
zation the rosiglitazone group retained
a 39% lower incidence of the compos-
ite outcome but had only 17% more re-
version to normoglycemia than the
placebo group (38). Thus, limited expo-
sure to a TZD (in this case, rosiglitazone,
but also troglitazone in the DPP [33]
and pioglitazone in ACT NOW [39]) ap-
pears to reduce the long-term inci-
dence of diabetes by delaying, rather
than reversing, the underlying disease
process.
The ORIGIN (Outcome Reduction
With Initial Glargine Intervention) trial
(16,40) explored the same question of
preventing diabetes by reducing b-cell
load, in this case with insulin therapy.
Adults with cardiovascular risk factors
who either had or were at risk for de-
veloping diabetes were randomized to
receive either insulin glargine or stan-
dard care. Although the study’s primary
focus was on cardiovascular outcomes,
incident diabetes among at-risk partici-
pants was also examined. After a mean
follow-up of 6.2 years, glargine reduced
the risk of diabetes by 28% compared
with standard care based on oral glu-
cose tolerance tests (OGTTs) performed
;1 month after insulin was stopped.
When participants were identified
through a second OGTT performed
;3 months later and those with uncer-
tain new diabetes diagnoses were in-
cluded, the total risk reduction was
31%. A 2-year passive follow-up study
of 4,718 of the original 12,537 ORIGIN
participants was consistent with a leg-
acy effect, with new diabetes cases oc-
curring in 41 and 48% of the glargine and
standard care groups, respectively,
when both confirmed and unconfirmed
cases were included (41).
Additional prevention studies have
been conducted with other pharmacolog-
ical agents. The international STOP-NIDDM
(Study to Prevent Non-Insulin-Dependent
Diabetes Mellitus) trial (17), a 2009 Japa-
nese study (18), and the U.K. Early Diabe-
tes Intervention Trial (EDIT) (19) all
investigated the preventive effects of
a-glucosidase inhibitors in individuals
with IGT. In STOP-NIDDM, participants re-
ceiving 100 mg of acarbose three times
daily for 3 years had a 25% reduction in
relative risk of diabetes compared with
placebo. Acarbose therapy also signifi-
cantly increased the rate of reversion to
NGT (17). In the Japanese study, partici-
pants receiving 0.2 mg of voglibose three
times daily for 4 years had a 40% reduction
in the relative risk of diabetes compared
with placebo and were significantly more
likely to achieve normoglycemia (18). EDIT
randomized 631 U.K. participants at risk
for diabetes based on two FPG levels of
99–139 mg/dL (5.5–7.7 mmol/L) to acar-
bose 50 mg, metformin 500 mg, or
matched placebo three times daily
in a 23 2 factorial study. After 3 years,
no statistical risk reductions with were
observed with acarbose or metformin
(8 and 37%, respectively) compared
with placebo (19). Although the final
EDIT results have not been fully report-
ed, no differences were seen in the rel-
ative risk for diabetes by 6 years for
acarbose (1.04, P = 0.81), metformin
(0.99, P = 0.94), or their combination
(1.02, P = 0.91). Interestingly, for those
with IGT at baseline, the relative risk of
diabetes was reduced by acarbose (0.66,
P = 0.046) but not by metformin (1.09,
P = 0.70), perhaps because the fasting
glucose level and BMI in this study were
lower than in the DPP. The investigators
concluded that the ability of therapies
to reduce the risk of diabetes may differ
for those with IGT versus those with IFG
(42).
TheinternationalNAVIGATOR(Nateglinide
and Valsartan in Impaired Glucose Toler-
ance Outcomes Research) trial (20) tested
whether treatment with themeglitinide
nateglinide reduces the risk of diabetes
and cardiovascular events in adults with
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IGT and cardiovascular disease or car-
diovascular risk factors. The study com-
pared nateglinide up to 60 mg three
times daily or valsartan therapy to pla-
cebo. During a median follow-up of 5
years, nateglinide did not significantly
reduce the cumulative incidence of dia-
betes compared with placebo (36 vs.
34%, respectively). There was no reduc-
tion in the nateglinide group in a core
cardiovascular composite outcome
that included death from cardiovascu-
lar causes, nonfatal myocardial infarc-
tion, nonfatal stroke, or hospitalization
for heart failure (7.9 vs. 8.3%, respec-
tively), and there was no reduction in
an extended cardiovascular composite
outcome that included the individual
components of the core composite out-
come as well as hospitalization for
unstable angina and arterial revascular-
ization (14.2 vs. 15.2%, respectively).
Furthermore, nateglinide therapy in-
creased the risk of hypoglycemia.
In the Swedish XENDOS (Xenical in the
Prevention of Diabetes in Obese Sub-
jects) trial (21), obese adults with either
NGT or IGT were randomly assigned to
lifestyle modification plus either orlistat
120 mg or placebo three times daily.
After 4 years, the cumulative incidence
of diabetes was 9.0% with placebo and
6.2% with orlistat, corresponding to an
overall risk reduction of 37.3%. Analyses
indicated that the preventive effect of
orlistat was explained by its effect on
participants with IGT at baseline, in
whom orlistat yielded a risk reduction
of 52%. Participants receiving orlistat
also had significantly greater mean
weight loss (5.8 vs. 3.0 kg with placebo),
which was not dependent on their glu-
cose tolerance status.
The international SCALE (Satiety and
Clinical AdipositydLiraglutide Evidence)
trial (22) investigated the effects of
the glucagon-like peptide 1 recep-
tor agonist liraglutide on weight and
cardiometabolic risk factors in obese
adults without diabetes. Participants
were randomly assigned to receive either
liraglutide 3.0 mg in once-daily injections
or placebo in addition to counseling on
lifestyle modification. After 56 weeks,
those receiving liraglutide lost signifi-
cantly more weight (difference –5.6 kg).
Weight loss of at least 5% body weight
was achieved in 63.2 and 27.1% of
the participants in the liraglutide and
placebo groups, respectively, and 33.1
and 10.6%, respectively, lost .10%
body weight. A1C, fasting glucose, and
fasting insulin levels decreased more
with liraglutide than with placebo, and
the liraglutide group also had lower glu-
cose and higher insulin and C-peptide
levels during OGTT. Insulin resistance
and b-cell function also improved with
liraglutide. The prevalence of prediabe-
tes at week 56 was significantly lower
with liraglutide (7.2 vs. 20.7% among
participants with baseline normoglycemia
and 30.8 vs. 67.3% among those with
baseline prediabetes), and type 2 diabe-
tes developed in fewer patients receiv-
ing liraglutide than with placebo (4 vs. 14
cases).
Taken together, these studies con-
vincingly support lifestyle modification
focusing on healthful eating and in-
creased physical activity and various
pharmacological therapies as viable
strategies for preventing type 2 diabe-
tes. However, they also raise important
new questions, such as 1) how best to
identify the most appropriate target
populations for intervention, 2) how to
disseminate lifestyle interventions in
the most cost-effective manner, and 3)
how expanding preventive pharmaco-
therapy options might further the goal
of reducing diabetes rates worldwide.





Many longitudinal studies have outlined
the trajectories of the metabolic factors
(i.e., insulin secretion, insulin sensitivity,
and 2-h glucose levels) preceding diag-
nosis. For example, Taba´k et al. (43)
showed that insulin secretion and insu-
lin actionmay be considered to be in the
normal range until 2–6 years before diag-
nosis, when abruptmetabolic changes re-
sult in deterioration of fasting and 2-h
postload glucose levels. Each of the three
clinical categories used to identify the
prediabetic state (isolated IFG, isolated
IGT, and combined IFG and IGT) may
represent a distinctive pathophysiology
(44). Individuals in each of these cate-
gories have an elevated diabetes risk,
and responses to interventionsmay differ
based on the category and severity of the
abnormality. Thus, attempts to curb the
prevalence of diabetes must focus on
effectively screening, identifying, and
treating people who are at increased
risk by virtue of being in one of these
categories.
However, there is not uniform agree-
ment on the specific approach to take.
Given the different trajectories of fast-
ing glucose, postprandial glucose, and
insulin levels before diagnosis, what
specific point would be the most appro-
priate at which to intervene?
Determining Appropriate Diagnostic
Criteria for Prediabetes
The current diagnostic recommendations
for diabetes are an FPG level$126mg/dL
(7.0 mmol/L) or a 2-h plasma glucose dur-
ing an OGTT $200 mg/dL (11.1 mmol/L)
(Fig. 1). These criteria historically were
based on thresholds for the risk of reti-
nopathy (45–48). The term “impaired glu-
cose tolerance,” comprising people at
high risk to progress to diabetes, was es-
tablished in 1979, and its definition (2-h
OGTT glucose levels between the normal
and diabetic values) essentially has not
changed since then (46). Inmost diabetes
prevention studies to date, subjects have
had IGT (i.e., a 2-h OGTT glucose level of
140–199 mg/dL [7.8–11.0 mmol/L]).
The controversy regarding appropri-
ately diagnosing prediabetes and target-
ing interventions relates to the use of
other suggested criteria (FPG and A1C).
For example, in 2003, an American Diabe-
tes Association (ADA) Expert Committee
suggested that the FPG threshold for IFG
be reduced from 110mg/dL (6.1 mmol/L)
to 100mg/dL (5.6mmol/L) (48). The com-
mittee suggested that this lower cut point
may improve the sensitivity of the predic-
tion of diabetes risk, but this change has
not been universally accepted because
the specificity is markedly reduced by
lowering the threshold; thus, many peo-
ple whomay not progress to diabetes are
being labeled as having prediabetes (49).
In 2009, an A1C cut point of $6.5% (48
mmol/mol) was introduced to diag-
nose diabetes, and this was later en-
dorsed by a WHO consultation committee
(50,51). Since 2010, ADA has recom-
mended that an A1C range of 5.7–6.4%
(39–46mmol/mol) be considered indica-
tive of prediabetes (45). However, other
organizations have not agreed with these
FPG and A1C cut points (51–53). A recent
meta-analysis evaluated progression
rates by prediabetes definition. It was
found that A1C values of 6.0–6.4% (42–
46 mmol/mol) might identify individuals
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at lower risk than other prediabetes def-
initions, butmore research is needed (54).
The success of any broad-based pre-
vention strategy will hinge on attaining
consensus regarding the most appropri-
ate diagnostic test and the glycemic cut
point at which to begin intervention. The
current lack of concordance on this issue
is not a trivial matter and has tremendous
clinical implications (55). At present, life-
style intervention has been shown to be
unequivocally effective in reducing diabe-
tes incidence only in subjects with iso-
lated IGT or combined IGT and IFG and
in subjects with A1C levels of 6.0 to
,6.5% (42 to ,48 mmol/mol). Without
intervention, these individuals have a
much higher incidence of diabetes than
do individualswho are classified as having
prediabetes by other criteria. Existing
data are not sufficient to make evi-
dence-based recommendations for those
with prediabetes classified by other crite-
ria; targeted studies are needed to pro-
vide more specific information.
Clinical Implications of the Prediabetes
Diagnosis
More general agreement exists regarding
the clinical implications of the prediabetic
state. First and foremost, prediabetes is
linked to microvascular complications (56–
59). For example, using data from the Na-
tional Health and Nutrition Examination
Survey (NHANES) and defining “prediabe-
tes” as an FPG $100 mg/dL (5.6 mmol/L)
but ,126 mg/dL (7.0 mmol/L), Plantinga
et al. (56) reported that the prevalence
of chronic kidney disease was 17.7% in
individuals with prediabetes compared
with 10.6% in those with no diabetes
and 39.6% and 41.7% in individuals with
diagnosed or undiagnosed diabetes, re-
spectively. Second, each category of pre-
diabetes (i.e., IFG, IGT, or a combination
of both) increases the relative risk and
incident rate of progression to diabetes,
although isolated IFG has less predictive
value (60). Although previous studies pri-
marily usedan IFGcutpoint of$110mg/dL
(6.1 mmol/L), there is evidence that lower
(but still elevated) 2-h glucose and A1C val-
ues also confer risk (61–63), although data
on FPG are less clear.
Onemajor factor to consider is whether
the ADA-recommended lower thresholds
for A1C and IFG are associated with higher
cardiovascular risk. Understanding that
risk is a graded continuum, one would ex-
pect these values to confer some level of
increased risk, and there is evidence to
support this (64–66), although some stud-
ies have demonstrated less excess risk
than others. For example, in the U.S.
MESA (Multi-Ethnic Study of Atheroscle-
rosis) trial (64), IFG was defined as no
type 2 diabetes and a fasting glucose of
100–125 mg/dL (5.6–6.9 mmol/L) and
was associated with an increased inci-
dence of cardiovascular events in univar-
iate, but not multivariate, analysis
compared with those with normal fast-
ing glucose. Data from the Emerging Risk
Factors Collaboration (ERFC) (65) sug-
gested that “there are generally contin-
uous associations between fasting
glucose levels greater than 100 mg per
deciliter and risk of death, supporting
the view that hyperglycemia (or some fac-
tor closely related to it) may be directly
relevant.” In addition, Xu et al. (66) per-
formed a meta-analysis on the risk of
coronary heart disease (CHD) using differ-
ent IFG criteria. They found an increased
risk of CHD when FPG was as low as
100 mg/dLdthe lower ADA cut point
for IFGdand concluded that “these re-
sults reaffirm the importanceof screening
for prediabetes using the ADA criteria.”
Collectively, these studies indicate the
clinical implications of the continuum of
excess risk for microvascular complica-
tions, macrovascular complications, mor-
tality, and type 2 diabetes even at the
lower values within the glycemic range
that defines prediabetes (67).
Disseminating Lifestyle Interventions
Cost-Effectively
Numerous efforts have been made to
translate lifestyle interventions into real-
world practice, although risk reductions
generally have not matched the levels
achieved in proof-of-concept research
studies (68–79). This is not surprising in
that clinical practices face different chal-
lenges from those in research settings,
including personnel training, funding
and reimbursement schemes, competing
needs in clinics, and compliance and ad-
herence barriers (80).
Clearly, more work is needed to make
widespread practical use of the lessons
learned thus far, to tailor simple and prac-
tical interventions to specific populations
and individuals, and to identify patients
for whom lifestyle modification may not
be enough. A great deal of information is
now available about the predictors of inci-
dent diabetes and of successful risk reduc-
tion through lifestyle intervention (Table 2)
(5,7,11,12,27–29,34,35,76,81–97). These
findings will help to guide future efforts
to determine the most appropriate candi-
dates for widespread translation initiatives
among high-risk individuals. Other remain-
ing questions regarding lifestyle interven-
tion include the following:
c How much do the dietary and exercise
components contribute individually to
reducing diabetes risk and delaying or
preventing the onset of the disease, or
are the two inextricably linked? How
much weight loss maintained over
how many years is required for sus-
tained prevention of type 2 diabetes?
Figure 1—Criteria for diagnosing diabetes and prediabetes. Diagnosis of diabetes is made on the
basis of an FPG level$126mg/dL (7.0 mmol/L), a 2-h plasma glucose level during an OGTT$200
mg/dL (11.1 mmol/L), or an A1C $6.5% (48 mmol/mol). When using A1C for diagnosis, it is
important to take the patient’s age, race/ethnicity, and anemia/hemoglobinopathy status into
consideration. Diabetes can also be diagnosed based on unequivocal symptoms and a random
plasma glucose value$200 mg/dL (11.1 mmol/L). Any abnormality by any testing method must
be repeated and confirmed on a separate day. For the diagnosis of prediabetes, cut points are
not as well established. A 2-h plasma glucose during an OGTT of 140–199mg/dL (7.8–11.0mmol/L)
is known as IGT and considered indicative of prediabetes, but recommended FPG and A1C cut
points for prediabetes have varied (FPG $100–125 or $110–125 mg/dL [5.6–6.9 or 6.1–6.9
mmol/L] andA1C$5.7–6.4 or$6.0–6.4% [39–46or 42–46mmol/mol]). Adaptedwith permission
from American Diabetes Association (45).
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Table 2—Predictors of diabetes risk reduction through lifestyle intervention
Study Relevant findings
Da Qing IGT and Diabetes Study (5,27–29,81) c Diet, exercise, and a combination of diet and exercise intervention for 6 years in
Chinese adults with IGT were equally effective in reducing diabetes incidence.
c Interventions were effective in people with a BMI higher or lower than 25 kg/m2.
c Benefit could not be wholly ascribed to changes in BMI.
c Interventions were most effective in those with less insulin resistance and
greater insulin secretion at baseline.
c Reduced cumulative diabetes incidence persisted for at least 17 years after the
termination of the active intervention.
c Lifestyle intervention was associated with a subsequent lower incidence of
severe retinopathy and lower mortality.
Finnish Diabetes Prevention Study (DPS) (82–89) c Lifestyle intervention was most effective among the oldest participants and
those scoring highest on a composite risk assessment at baseline. This scoring
instrument or others like it may be useful for identifying individuals most likely to
benefit from intensive lifestyle intervention.
c Participants who had greater insulin sensitivity and better insulin secretion
during the study were less likely to progress to diabetes during a mean follow-up
of 6 years. Regression to NGT was more strongly associated with greater insulin
secretion than with better insulin sensitivity.
c Participants with greater improvements in weight and BMI during the first year
were less likely to develop diabetes. Thus, BMI reduction may be a key goal to
improve insulin sensitivity, preserve insulin secretion, and ultimately prevent or
delay diabetes.
c Achievement of each of the study’s five lifestyle goals significantly decreased
risk. None of the participants who achieved at least four of the five goals
developed diabetes by year 4.
c Participants with longer typical sleep durations had a higher risk of developing
diabetes in the control group but not in the intervention group; lifestyle
intervention was similarly effective regardless of participants’ sleep habits. Thus,
lifestyle intervention may reduce the excess risk conferred by longer sleep
duration.
c Several genetic variants conferred higher diabetes risk. Post hoc analyses
showed that although lifestyle intervention was effective regardless of family
history of diabetes its effectiveness varied markedly according to participants’
genetic variant status. This demonstrates the potential role of genotype in
diabetes prevention efforts.
Diabetes Prevention Program (DPP) (7,34,35,90–94) c Short- and long-term effects of intensive lifestyle intervention were greatest
among older participants, those with greater baseline insulin sensitivity and
insulin secretion, and those with greater improvements in each during the active
study period.
c For women with a history of GDM, lifestyle modification and metformin were
similarly effective, whereas for women without previous GDM, only lifestyle
intervention reduced diabetes risk.
c Lifestyle intervention was similarly effective in those with and without higher
genetic risk.
c The presence or absence of diabetes-related antibodies did not affect diabetes
risk or predict responses to intervention.
c Individuals from any group who regained NGT at least once during active
intervention reduced their diabetes risk by 56% during long-term follow-up
comparedwith those with persistent prediabetes. Thus, even transient reversion
to NGT by any means appears to lower future diabetes risk. Reversion was more
common in the lifestyle group and was more likely in participants who achieved
greater weight loss, were younger, and had lower glucose levels and betterb-cell
function at baseline. Paradoxically, lifestyle group members who did not revert
to NGT during the study were actually at higher risk during follow-up, perhaps
because of a particularly strong susceptibility (genetic or environmental) to
diabetes. Thus, a combination of interventions may be needed for individuals
whose dysglycemia is not reversed through lifestyle modification alone.
Indian Diabetes Prevention Programme-1 (IDPP-1) (95) c Baseline A1Cwas themost significant predictor of diabetes; however, preventive
interventions were similarly effective across A1C subgroups.
c Lifestyle intervention reduced diabetes risk in this population independent of
weight loss.
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c Are the beneficial effects of exercise
or increased leisure-time activity ef-
fective independent of weight loss
among people who are overweight/
obese and those who are of normal
weight? Is delay or prevention of di-
abetes possible in the absence of
weight loss in some populations?
c Is it appropriate to group individuals
with isolated IFG together with those
who have IGT or a combination of
both as the target for preventive in-
terventions? If not, what strategies
might be necessary to reduce diabe-
tes risk in people with each type
of metabolic dysregulation (or, for
that matter, with higher or lower
A1C values)?
c Howmight lifestyle interventions that
have proven effective in structured
research settings be implemented
successfully through large-scale pub-
lic health initiatives?
Expanding Pharmacotherapeutic
Options: Moving Toward a
Prevention-Related Indication
for Metformin
Relying on diet and physical activity is not
enough to delay progression for some at-
risk individuals because long-term adher-
ence to healthy lifestyle behaviors can be
difficult (26). Furthermore, as previously
noted, interventions implemented in re-
search studies can be prohibitively labor
intensive and expensive to deliver in real-
world settings, where they face different
obstacles (80). In addition, the costs of
prevention services, suchas lifestylemod-
ification programs and health coaching,
typically have not been reimbursed by
payers (25). The recently announced
findings supporting the cost-effectiveness
of the NDPP (23,24) are encouraging, as
is a recent recommendation from theU.S.
Preventive Services Task Force that obese
adults aged 40–70 years who do not have
symptomsofdiabetes should be screened
for abnormal blood glucose in the primary
care setting (98). Although these and
other public health initiatives (99–103)
could soon improve this situation, current
reimbursement structures and a shortage
of qualified lifestyle coaches in primary
care and nonmedical settings remain
problematic.
For these reasons, preventive pharma-
cotherapy has been proposed as an ad-
junct to lifestyle modification (39). As
reviewed above, strong evidence from
randomized controlled trials has shown
the potential of various pharmacological
therapies to prevent progression to
type 2 diabetes in people with IGT (7–10,
13–22,33,104). The preventive effects of
these agents, although not fully under-
stood, appear to be related primarily to
their ability to lower blood glucose and to
preserve or delay the deterioration of
b-cell function and thereby modify the
disease progression (105), as demon-
strated in the DPP (90). TZDs improve in-
sulin sensitivity and glucose utilization
and also have direct, positive effects on
the b-cells; a-glucosidase inhibitors re-
tard carbohydrate absorption and lower
postprandial hyperglycemia, reducing the
b-cell load; and metformin, a biguanide,
suppresses hepatic glucose production.
Each of these mechanisms potentially
could modulate factors related to preser-
vation of b-cell function by reducing the
demand for insulin secretion.
As preventive monotherapy, only
metformin has been studied for longer
than ;3 years, and reductions in diabe-
tes incidence have generally dissipated
after discontinuation of glucose-lowering
drugs (26). In addition, TZDs have been
plagued with concerns regarding serious
adverse events, and acarbose is associ-
atedwith gastrointestinal (GI) symptoms
and greater adherence problems
(17,104,106). Some newer obesity and
diabetes medications (e.g., orlistat and
glucagon-like peptide 1 receptor ago-
nists) (21,22,107) have the potential for
diabetes prevention based on their pos-
itive effects on weight and cardiovascu-
lar risk factors and possibly also b-cell
function and protection. However, such
agents are costly, some are injectables
(which may pose a barrier for some
people), and all require further study
in the population with prediabetes
(26,108).
Metformin, with proven effective-
ness, long-term safety (109), and cost-
effectiveness as the first-line type 2
diabetes treatment (110), is the most
likely candidate for widespread use in
diabetes prevention (100). Although
less effective overall than lifestyle inter-
vention in the DPP, it was as effective as
lifestyle modification for younger partic-
ipants, very obese participants ($35
kg/m2), and women with a history of GDM.
However, it was no more effective than
placebo in older participants (.60 years
of age) (7,111). A recent risk-based re-
analysis of the DPP (112) found that the
benefit of metformin was unevenly dis-
tributed within the study population such
that only subjects in the highest-risk
Table 2—Continued
Study Relevant findings
Indian text-messaging intervention study (76,96,97) c Participants who regained NGT by 6 months reduced their risk of progression to
diabetes by 75%by year 2 comparedwith thosewho did not return to NGTwithin
the first 6 months. Better b-cell function at baseline and its improvement during
the study were associated with reversion to NGT by 2 years.
c Progression to diabetes was associated with declining b-cell function throughout
the study period.
Zensharen Study for Prevention of Lifestyle
Diseases (11)
c Lifestyle intervention was highly effective in participants with combined IGT and
IFG and in those with a baseline A1C $5.6% (Japan Diabetes Society method).
c Lifestyle intervention was ineffective in participants with isolated IFG and in
those with a baseline A1C ,5.6%.
Japanese study on prevention of type 2 diabetes by
lifestyle intervention (12)
c The cumulative 4-year incidence of diabetes, based on confirmed diagnostic FPG
levels of 140mg/dL (7.8 mmol/L) or higher, was 3.0% in the intensive and 9.3% in
the conventional group.
c Changes in BMI only partially accounted for the lower incidence in the intensive
group.
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quartile experienced marked risk re-
duction, whereas the remaining sub-
jects received little or no benefit. Since
2008, ADA has recommended consid-
eration of metformin therapy for indi-
viduals who are at very high risk for
diabetes (currently including individuals
who are ,60 years of age, are very
obese, have a history of GDM, or have
IGT, IFG, or an A1C of 5.7–6.4% [39–46
mmol/mol]) (113).
Despite this recommendation, met-
formin use for diabetes prevention has
been minimal in many countries. Cost
may not be a major issue, but GI side
effects and the lack of perceived benefit
with no measurable targets may play a
role in the low rate of metformin use in
prediabetes. For example, a recent eval-
uation of metformin prescription rates
in a nationwide sample of .17,000 in-
sured adults aged 19–58 years with pre-
diabetes in the U.S. found that only 3.7%
were prescribedmetformin in the 2010–
2012 period. Even within a subgroup of
individuals with a BMI .35 kg/m2 or a
history of GDMdcharacteristics specif-
ically identified in ADA guidelinesdonly
7.8% received a metformin prescrip-
tion (114). Although more research is
needed to pinpoint the reasons for this
lack of uptake for metformin use in pre-
diabetes, the authors suggested that
providers’ lack of knowledge about DPP
and the natural course of prediabetes,
reluctance on the part of patients and
providers to “medicalize” prediabetes,
and the lack of a metformin prediabe-
tes indication approved by the U.S.
Food and Drug Administration (FDA)
and similar agencies in other countries
all may play a role. That said, a prediabe-
tes indication for acarbose has been ap-
proved in several countries (115), but it
is uncertain how often that agent is pre-
scribed for this use.
The lack of a prevention-related indi-
cation for metformin poses a significant
barrier to more widespread use, but
perhaps not an insurmountable one. Al-
though conventional wisdom holds that
the FDA is reluctant to approve such an
indication for any drug, the agency’s
2008 draft guidance for industry on de-
veloping diabetes drugs seems to sug-
gest otherwise (116). This document,
although never finalized, outlines the
FDA’s expectations for “products in-
tended to prevent the development of
diabetes” (116). These expectations
include that supporting research studies
need to 1) be conducted in populations
of high-risk individuals (e.g., those
with IGT, IFG, or a history of GDM); 2)
include a washout period to confirm
that the drug truly delays, rather than
merely masks, progression of the under-
lying disease process; 3) be of substan-
tial duration and size; and 4) include as
possible end points either delay in
type 2 diabetes diagnosis or reduction
in the proportion of patients diagnosed
with type 2 diabetes relative to placebo.
Theguidancenotes that, in theabsence
of a clearly defined “clinically meaningful
effect size,”merely delaying a diagnosis of
diabetesmay not bea sufficiently tangible
benefit againstwhich to judge risks. It sug-
gests, however, that certain supporting
outcomes, such as demonstration of a du-
rable delay indiabetesonset after therapy
ends or evidence of delay or reduction of
micro- or macrovascular complications,
could strengthen a candidate drug’s
claim. In addition, the guidance states
that the FDA’s expectations for the safety
of prevention-related products are likely
to behigher than for drugs aimed at treat-
ing type 2 diabetes.
Notably, the FDA guidance does not
suggest that a candidate agent must be
supported by evidence that it actually
“prevents” type 2 diabetes but rather
that it durably delays disease onset
and thereby can be expected to reduce
long-term complications. Some would
reserve the term “prevention” for inter-
ventions that, at least in a significant
proportion of individuals, forestall the
onset of diabetes for decades or longer.
Others may take a more pragmatic per-
spective and hold that the terms “reduc-
tion,” “prevention,” and “delay” may be
considered close enough on the same
spectrum to be used interchangeably
(117). The distinction may be important
to the FDA, which likely would set a
higher evidence bar for a “prevention”
indication than it would for an indication
“for the treatment of prediabetes” or
“for reducing the risk of developing
type 2 diabetes.” To date, the only evi-
dence in support of strictly defined “pre-
vention” has come from the previously
mentioned DPP cost-effectiveness anal-
ysis (36) showing that the effects of the
metformin intervention, projected over
a lifetime, would not only delay diabe-
tes but also reduce its absolute incidence
by 8%.
Consistent with the FDA guidance,
however, the evidence base for metfor-
min may already be substantial enough
to support approval of some form of
prevention-related indication. Some
work may be necessary to develop ex-
pert consensus with regard to what
constitutes a clinically meaningful delay
in the development of diabetes in the
context of metformin’s known benefits
and risks; this would be analogous to a
previous successful initiative to estab-
lish measures of C-peptide as the pri-
mary efficacy end point for new type 1
diabetes drugs (118). Notably, the FDA
has awarded cardiovascular prevention
indications for statins on the basis of
results from a single robust trial showing
significant reductions in tangible cardio-
vascular events (119).
Admittedly, the DPP did not evaluate
participants’ diabetes status off therapy
by including a metformin washout pe-
riod. In its guidance, the FDA reasonably
asks for confirmation that normal glu-
cose regulation persists after washout
to exclude the possibility that a glu-
cose-lowering agent is not simply main-
taining normoglycemia in those who
actually have progressed to diabetes.
Evaluating diabetes status after washout
must be distinguished from demonstrat-
ing the durability of the diabetes-delaying
effect. The latter is determined by restart-
ing treatment and determining at subse-
quent time points (each after treatment
washout) what proportion of the popula-
tion retains normal glucose regulation
status. This distinction is less important
for trials of long duration with a single
washout evaluation at the end and
more important for shorter trials with
a single end point, for which durability
remains an open question, and for long
trials with intermediate end points. Mea-
suringdurability becomesmore important
when the safety profile of a candidate
drug is not so benign. Here, weighing the
durability of benefit against cumulative
adversity would be an important aspect
of estimating theoverall benefit-to-risk re-
lationship of what for some could be a
lifelong therapy.
In the case of metformin, the long-
term safety profile is well established,
making the drug suitable for lifelong
use once it is started for prevention, al-
though there have been associated GI
tolerability issues and concerns about
vitamin B12 deficiency and anemia, as
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well as neuropathy in those with low
vitamin B12 levels (120). Similar to cur-
rent ADA recommendations, the indica-
tion for metformin should limit its use to
subpopulations found in the DPP to be
at high risk (i.e., those with a history of
GDM, who are very obese, or who have
more severe or progressive hyperglyce-
mia) until additional evidence supports
expansion of the indicated population.
Of interest in this regard, metformin re-
duced IGT progression to diabetes in the
IDPP’s lean Indian population about as
well as it did in the DPP’s obese popula-
tion (7,8).
Key practical questions are: how
could approval of a new metformin in-
dication be achieved, and who will lead
this effort? The conventional mecha-
nism would be for one or more of the
companies marketing metformin in the
U.S. to compile and submit a supple-
mentary new drug application contain-
ing the data and other necessary
information to allow the FDA to approve
the indication. However, these compa-
nies may not wish to spend the signifi-
cant resources required for such an
application given that metformin is al-
ready available in generic form. Realiz-
ing the long-term societal benefits of
type 2 diabetes prevention may require
other avenues for FDA approval (25).
One approach could be for the FDA to
receive a comprehensive package of ev-
idence and other relevant material and
call an advisory committee for a full pub-
lic discussion. With a positive vote of its
advisory committee, the FDA could con-
clude that the indication should be
granted and allow companies with ap-
proved metformin new drug applications
to add the new indication to their labels.
An organization such as ADA could very
appropriately lead the effort to compile
the briefing package for the FDA and fa-
cilitate other supportive actions.
UNMET RESEARCH NEEDS
We need to learn more about racial and
ethnic differences in responses to life-
style and, particularly, pharmacological
interventions. Are there meaningful dif-
ferences, or are they more perceived
than real because different populations
were not compared in the same study?
The similar effectiveness of the DPP in-
terventions in five ethnic groups sug-
gests that this may be more theoretical
than real (7).
Much remains to be learned about
the genetics of diabetes risk, the effects
of genetics as a modifier of prevention
interventions, and the potential role of
genetic testing to identify appropriate
subjects for future research. In this re-
gard, genetics has been somewhat dis-
appointing to date. Compilation of
genetic risk scores has demonstrated
that greater genetic risk is associated
with a greater likelihood of progression
to diabetes. However, this work has also
demonstrated that a high genetic risk
score in adults is typically also associ-
atedwith elevated glucose levels, mean-
ing that glucose itself is as good a
predictor and certainly less expensive.
Thus, the true utility of genetic risk
scores may be in identifying young indi-
viduals who are at the greatest risk and
initiating preventive therapy in them
well before their glucose levels start to
increase substantially.
More detailed evidence is needed to
inform efforts to tailor preventive mea-
sures based on patients’ phenotype, ge-
notype, composite diabetes risk scores,
personal characteristics, socioeconomic
factors, and other relevant parameters.




Carefully conducted landmark preven-
tion trials have provided more than
enough evidence that prevention or de-
lay of type 2 diabetes is possible in high-
risk individuals. Clearly, the next step is
to implement these strategies, and new
technologies and innovations offer
promising ways to reduce the labor
and costs associated with scaling up pre-
vention initiatives on a population level.
Individuals can be screened for predia-
betes in numerous low-cost ways for en-
rollment in an intervention. Community
or workplace health screenings, pro-
vider referrals, and reviews of electronic
medical records all can be leveraged to
screen for diabetes risk. Individuals can
also self-screen using one of the many
available risk scoring instruments. Such
risk questionnaires, originating from
many sources in various populations,
are available on the Internet and can
be publicized through traditional adver-
tising and social media (82,121–125).
Throughout the world, countries are
now developing practical, affordable
population-based programs that can
be tailored for individual and cultural
differences and implemented relatively
inexpensively. Some of these programs
are described below, and their reported
results, where available, are summa-
rized in Table 3 (24,68,76–78,126–129).
Taking advantage of new technolo-
gies can aid in the translational effort
by reducing costs and expanding reach
to a wide audience. For example, an In-
dian study assessed the effectiveness
of a text-messaging lifestyle interven-
tion and convincingly demonstrated
that a low-cost, low-labor program of-
fering lifestyle modification support
through a widely available medium
can produce clinically meaningful out-
comes (76). Similar approaches are be-
ing implemented in other countries,
some under the auspices of the WHO/
International Telecommunication Union
Be He@lthy, Be Mobile program (130).
Elsewhere, numerous public health
initiatives have begun translating preven-
tion research into effective community-
based, or even nationwide, interventions.
The Finnish National Diabetes Prevention
Program (FIN-D2D) (77,131,132) was the
first of these efforts. Implemented in
2003 in five districts covering a popula-
tion of 1.5 million, it encompasses three
concurrent strategies: a high-risk strategy
aimed at incorporating diabetes preven-
tion and cardiovascular risk reduction into
routine primary care using existing
resources, a population strategy focused
on raising awareness, and an early treat-
ment strategy for individuals identified
through screening as having diabetes.
The ultimate goal of FIN-D2D is to refine
and expand this multistrategy approach
to serve all of Finland. The Finnish expe-
rience also has been used in the large
European effort DE-PLAN (Diabetes in
Europe: Prevention Using Lifestyle, Phy-
sical Activity andNutritional Intervention)
to develop screening for type 2 diabetes
risk followed by lifestyle programs in sev-
eral local settings, mainly in primary care
(133). This has been further elaborated
within the IMAGE (Development and Im-
plementation of a European Guideline
and Training Standards for Diabetes Pre-
vention) network, which has developed
tools for the implementation of preven-
tion in practice (134).
The second large-scale prevention
program reported was Victoria, Aus-
tralia’s Life! Taking Action on Diabetes
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Table 3—Sample translational prevention initiatives and their reported outcomes
Study or initiative Findings/results
Indian text-messaging intervention study (76) After 2 years, participants receiving twice-weeklymotivational textmessages had a
36% relative reduction in diabetes risk compared with those receiving standard
advice but no text messages.
Finnish National Diabetes Prevention Program
(FIN-D2D) (77)
After 1 year, average weight loss in this high-risk population was 1.3 kg in men and
1.1 kg in women, with a 1.3-cm reduction in waist circumference. Decreases
in blood pressure were 0.8 mmHg systolic and 1.5 diastolic in men, and 1.9 and
1.6 mmHg, respectively, in women. Total cholesterol, LDL cholesterol, and
triglyceride levels decreased by 5–8% inmenand 2–5% inwomen.Overall, 17.5%
of subjects lost $5% of their body weight, 16.8% lost 2.5–4.9% weight, 46.1%
maintained their baseline weight, and 19.6% gained$2.5% weight. The relative
risk of diabetes was 0.31 in the group who lost $5% weight, 0.72 in the group
who lost 2.5– 4.9% weight, and 1.10 in the group who gained$2.5% compared
with the group who maintained weight.
Australian Life! Taking Action on Diabetes program (78) Between 2007 and mid-2011, there were .14,800 referrals to the program, and
.8,400 individuals started the program. Participants who attended the first 5
sessions (offered every 2 weeks) lost amean 1.4 kg in weight and 2.5 cm in waist
circumference; those who also attended the sixth session (offered 8 months
after the first) lost a mean 2.4 kg in weight (2.7% weight) and 3.8 cm in waist
circumference, for an imputed potential diabetes risk reduction of 21–39%.
VA MOVE! Weight Management Program (68) Retrospective, observational analysis found a significant, dose-dependent, inverse
association between incident diabetes and participation. Compared with
nonparticipation, intense and sustained participation (at least eight sessions within
6 months over at least a 4-month span) was associated with a 33% reduction in
diabetes incidence, and lower-intensity participation yielded a 20% reduction in
diabetes incidence. Those who participated intensively also lost more weight than
low-intensity participants (–2.2 vs. –0.64%over 3 years). However, the programhas
not reached a substantial proportion of the eligible population; only 13%
participated in at least one session between 2005 and 2012.
Special Diabetes Program for Indians–Diabetes
Prevention (SPDI-DP) (126)
More than 2,500 participants started the 16-session program by 31 July 2008, with
clinical assessments performed at baseline, soon after completing the program,
and annually for up to 3 years. Crude incidence of diabetes was;3.5% per year
among those who finished all 16 sessions, whereas it more than doubled (7.5%
per year) among those who did not finish the program. Participants on average
lost 9.6 lb immediately after completing the program, representing a 4.4%
weight loss. This attenuated over the three annual visits but still differed
significantly from no weight loss. By the end of the program sessions, 22.5% of
participants had achieved the 7% weight loss goal; at the 3-year follow-up,
17.5% had achieved this goal. The percentage of participants achieving the 150
min/week exercise goal increased from 22% at baseline to 56% after the
program and was $38% at each of the annual assessments. Participants also
had significant improvements in blood glucose, blood pressure, and lipid
parameters throughout the follow-up period.
DEPLOY (Diabetes Education & Prevention with a Lifestyle
Intervention Offered at the YMCA) pilot study (127,128)
and YMCA Diabetes Prevention Program (129)
In the DEPLOY pilot study, body weight at 6 months decreased by a mean 5.7 kg or
6.0% in intervention participants and 1.8 kg or 2.0% in control subjects; this
difference persisted through 12 months, with no racial or sex differences. Also,
significant between-group differences in total cholesterol levels at both follow-
up points were observed. At 4 and 12 months, the intervention group had
significant decreases in 10-year coronary heart disease risk of 3.28 and 2.23%,
respectively, comparedwith control subjects, who had a decrease in 10-year risk
of 0.78% at 4 months and an increase in risk of 1.88% at 12 months.
As of December 2015, 39,435 individuals had attended at least one program
session at one of 202 YMCA centers in 43 states. The average weight loss among
participants was 4.7% at the end of the 16 sessions and 5.4% by 1 year. On
average, participants undertook 157.5 min/week of physical activity.
NDPP/Medicare/YMCA demonstration program (24) Throughthisprogram, fundedbyCMSunder theAffordableCareAct, eligibleMedicare
beneficiaries at high risk for diabetes attended initial weeklymeetings andmonthly
follow-up sessions with a lifestyle coach to address long-term dietary and lifestyle
modification to reduce their risk for diabetes.Meanweight loss was 4.7% for those
whoattendedat least fourweekly sessions and5.2%for thosewhoattendedat least
nine sessions. More than 80% of recruited participants attended at least four
sessions. When compared with similar Medicare beneficiaries not in the program,
CMSestimateda savings of $2,650 for each enrollee over a 15-monthperiod,which
was more than enough to cover the cost of the program.
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program (78). Established in 2007 and
built in part on the Finnish experience, this
statewide program has been implemented
in a systematic approach featuring a struc-
tured group intervention, standardized
facilitator training and accreditation, a
facilitator payment process linked to return
of data, a participant manual, a continuous
quality improvement process, and ongoing
evaluation. TheprogramusesanAustralian
risk tool to screen potential participants
and a multifaceted social marketing and
communications plan to raise awareness
and facilitate recruitment.
In Singapore, several initiatives have
been launched as part of the govern-
ment’s Healthy LivingMaster Plan to en-
courage the population in general, and
individuals with prediabetes specifically,
to adopt lifestyle changes to reduce
their diabetes risk (135–138). A low-
cost, nurse educator–led prediabetes in-
tervention program offers participants
three individual counseling sessions at
community centers or primary care clin-
ics and telephone follow-up after 6, 9,
and 12 months. OGTTs are performed
after 1 year to determine whether par-
ticipants’ dysglycemia has improved. In
addition, the Healthier Dining Pro-
gramme encourages food and beverage
companies to improve the nutritional
quality of their offerings, and the Work-
place Health Programme encourages
and provides resources to Singaporean
employers to provide an integrated ap-
proach to workplace health.
Israel recently launchedan innovativeap-
proach to prevention funded through a so-
cial impact bond. Under this arrangement,
private donors finance a 1-year intensive
intervention program in high-risk individu-
als. Health maintenance organizations and
the Israeli National Insurance Institute will
repay donors their original investment
plus a dividend based on cost reductions
realized through health improvements re-
sulting from the program (139).
In the U.S., numerous small DPP trans-
lational interventions have been imple-
mented in diverse settings using a variety
of innovative formats (69–75). On a larger
scale, the most promising programs to
date have been implemented in the vet-
eran population (68) and American Indian/
Alaska Native (AI/AN) communities (126)
and throughYMCAcenters throughout the
country (129).
The U.S. Department of Veterans Af-
fairs (VA) MOVE! Weight Management
Program (68) offers interactive educa-
tion sessions on nutrition, physical activ-
ity, self-management, and goal setting
for veterans who are overweight or
obese and have a weight-related disor-
der. Since 2005, .500,000 veterans
have participated, making MOVE! the
largest such program in the U.S.
The Special Diabetes Program for In-
dians–Diabetes Prevention (SPDI-DP)
(126) targets the AI/ANpopulation, which
has the highest diabetes prevalence rate
of any segment of the U.S. population (2).
Since 2006, the SPDI-DP has tested the
feasibility and impact of an adapted DPP
lifestyle intervention offered in native
communities that lack essential resources
and have diverse health care settings and
mobile populations, all of which pose
challenges to recruitment, retention,
and effectiveness. The program is being
offered through 36 health care programs
serving 80 AI/AN tribes in 18 states.
The YMCA Diabetes Prevention Pro-
gram is based on DEPLOY (Diabetes Ed-
ucation & Prevention with a Lifestyle
Intervention Offered at the YMCA), a
2005–2010 pilot study of a DPP-type in-
tervention adapted for community im-
plementation through YMCAs (127). The
year-long course is open to overweight
adults whomeet glucose criteria for pre-
diabetes, have had GDM, or have a high
score on a qualifying risk test. It provides
group education and counseling with
goals of 5–7% weight loss and $150
min/week of physical activity.
The YMCA program operates as part of
NDPP (23), which offers training for life-
style coaches and a formal recognition
process for high-quality intervention pro-
grams. NDPP has facilitated a partnership
between the YMCA and United Health
Group through which the YMCA receives
pay-for-performance reimbursement for
the program from insurers and private
employers. NDPP is now working to ex-
pand that partnership to include more
programs and payers and to refine amar-
keting strategy to increase referrals to
and participation in lifestyle intervention
programs nationwide.
In 2011, the U.S. Centers forMedicare
& Medicaid Services (CMS) awarded the
National Council of YMCAs of the USA
$11.8 million to enroll eligible Medicare
beneficiaries at high risk for diabetes in
a prevention program targeting weight
loss of$5%. The results of this initiative
led to the recent independent findings
in support of the expansion of the NDPP
model throughout the Medicare pro-
gram (24).
NEXT STEPS
The programs described above have de-
veloped innovative, pragmatic methods
of delivering lifestyle change interven-
tions; many have made use of the latest
information and communication tech-
nologies; and each has involved the ac-
tive cooperation of key stakeholders in
the medical community, nongovern-
mental organizations, and public and
private sector agencies. We are eagerly
awaiting reports of their outcomes and
hope that the components deployedwill
play an important role in reducing the
prevalence of a disease with such wide-
ranging personal, societal, and eco-
nomic consequences.
A logical early step in advancing pre-
ventive strategies may be for the dia-
betes medical community to reach
consensus on how to approach wide-
spread translational programs that po-
tentially can be implemented on a global
level. Although lifestyle interventions
are effective, our sole reliance on peo-
ple’s adherence to diet and physical ac-
tivity recommendations will not be
enough to delay progression for a large
portion of the at-risk population. Thus,
attention also must be given to recom-
mendations for pharmacological ther-
apy to yield long-term societal benefits
in the area of type 2 diabetes prevention
and reduction in diabetes complica-
tions, including cardiovascular disease.
Hence, in this Expert Forum, we also
discussed a possible alternative avenue
for FDA approval of a new prevention
indication for metformin. Specifically,
we developed a compelling argument
that the evidence base for metformin
already may be substantial enough to
support approval of such an indication.
We readily admit that additional work
will be needed, and many hurdles re-
main. Still, this is an exciting time for
diabetes prevention, and although
real-world translation is the next great-
est hurdle, it also represents the biggest
opportunity to stem the tide of the
global diabetes pandemic.
Acknowledgments. Writing and editing sup-
port services for this article were provided by
Debbie Kendall of Kendall Editorial in Richmond,
care.diabetesjournals.org Cefalu and Associates 1197
VA. The Editorial Committee recognizes that the
workof the journal andcontributions suchas this
Expert Forumwould not be possible without the
dedicated work and continued support of many
individuals. Specifically, the planning, logistics,
and funding of the meeting and the incredible
editorial support would not have been possible
without the tireless efforts of Chris Kohler and
his staff at the ADAPublishing office. In addition,
the Editorial Committee thanks Lyn Reynolds
and her staff in the ADA editorial office for
support and Anne Gooch at the Pennington
Biomedical Research Center for her valuable
assistance in helping to organize the Expert
Forum. W.T.C. is supported in part by National
Institutes of Health (NIH) grant 1U54-GM-
104940, which funds the Louisiana Clinical and
Translational Science Center, and NIH grant
P50-AT-002776.
Duality of Interest. W.T.C. has served as prin-
cipal investigator on clinical research grants
received by his institutions from AstraZeneca,
Janssen, MannKind Corp., and Sanofi and has
served as a consultant for Intarcia Therapeutics,
Adocia, and Sanofi. J.B.B. has been an investigator
and/or consultant under contracts between his
employer and the following companies: Adocia,
Andromeda, Astellas, AstraZeneca, Boehringer
Ingelheim,Bristol-MyersSquibb,DanceBiopharm,
Elcelyx, Eli Lilly and Co., F. Hoffman-La Roche, GI
Dynamics, GlaxoSmithKline, Halozyme, Intarcia
Therapeutics, Johnson & Johnson, Lexicon,
MacroGenics, Medtronic Minimed, Merck Sharp
& Dohme, Metavention, Novo Nordisk, Orexigen,
Osiris, Quest, Sanofi, Scion NeuroStim, Takeda,
Tolerex, and vTv Therapeutics. He is a consultant
to and has stock options from PhaseBio. J.T. has
received grant support from AstraZeneca,
Boehringer Ingelheim, Merck Sharp & Dohme,
Merck Serono, Regeneron, and Sanofi. He has re-
ceived honoraria for speaking engagements from
AstraZeneca, Eli Lilly and Co., Novo Nordisk, and
Sanofi and consulting fees from AstraZeneca,
Bayer Pharma, and Novo Nordisk. He is a stock
shareholder of Orion Pharma. G.A.F. is a panel
member/consultant for Acosti, Adocia, Arisaph,
Artemis, Bio-Cancer Treatment International Ltd.,
Becton Dickinson, BioCon, Diasome, Dompe´,
Emperra, Exsulin, Thermo Fisher Scientific, Gilead,
Hyperion, IMTherapeutics, Innoneo, Intarcia Ther-
apeutics, Islet Sciences, Lexicon, Locemia, Johnson
& Johnson, MannKind Corp., Mars, MediWound,
Melior, N-Gene, NuSirt, Royalty Pharma, Pfizer,
Rhythm, Sanofi, SkyePharma, Strongbridge Bio-
pharma, SynAgile, Takeda, Teva, Thermalin, The-
tis, ThromboGenics, Tolerion, VeroScience, and
Versartis. He is a stock/shareholder of Ammonett
Pharma, Exsulin Corporation, Locemia, Innoneo,
SynAgile, and Thetis. E.F. is an advisory board
member for Boehringer Ingelheim/Eli Lilly and
Co. and Merck Sharp & Dohme. He is a consul-
tant for AstraZeneca, GlaxoSmithKline, and Jans-
sen and a speaker for AstraZeneca, Boehringer
Ingelheim, Eli Lilly and Co., Merck Sharp &
Dohme, Mitsubishi, Novo Nordisk, Sanofi, and
Takeda. He receives research grant support
from Eli Lilly and Co. H.C.G. has received grant
support from AstraZeneca, Eli Lilly and Co.,
Merck Sharp & Dohme, and Sanofi; honoraria
for speaking engagements from AstraZeneca,
Berlin Chemie, Boehringer Ingelheim, Novo
Nordisk, and Sanofi; and consulting fees from
Abbott Pharmaceuticals, Amgen, AstraZeneca,
Boehringer Ingelheim, Eli Lilly and Co., Kaneq
Bioscience, Merck Sharp & Dohme, Novo Nor-
disk, and Sanofi. A.R. is an advisory board mem-
ber for AstraZeneca andMerck Sharp&Dohme. He
has received honoraria for speaking engagements
from Bayer, Eli Lilly and Co., Merck Sharp &
Dohme, Novartis, Novo Nordisk, and Sanofi.
The India Diabetes Research Foundation, ofwhich
he is president, has received research funding sup-
port fromAstraZeneca andNovartis. I.R. has served
on advisory boards for AstraZeneca/Bristol-Myers
Squibb, Boehringer Ingelheim, Eli Lilly and Co., Lab-
Style Innovations, Merck Sharp & Dohme, Novo
Nordisk, Orgenesis, Sanofi, and SmartZyme Innova-
tion; has been a consultant for AstraZeneca/Bristol-
Myers Squibb, FuturRx, Gili Medical, Insuline
Medical, Kamada, and NephroGenex; has
been a speaker for AstraZeneca/Bristol-Myers
Squibb, Boehringer Ingelheim, Eli Lilly and Co.,
Johnson & Johnson, Merck Sharp & Dohme, No-
vartis PharmaAG, NovoNordisk, Sanofi, and Teva;
and is a stock/shareholder in Glucome, Insuline
Medical, LabStyle Innovations, Orgenesis, and
SmartZyme Innovation. J.R. has servedonadvisory
boards and received honoraria or consulting fees
from AstraZeneca, Boehringer Ingelheim, Bristol-
Myers Squibb, Daiichi Sankyo, Eli Lilly and Co.,
Intarcia Therapeutics, Janssen, Merck Sharp &
Dohme, Novo Nordisk, and Sanofi. He has received
grants/research support from Asahi, AstraZeneca,
Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly and
Co., GlaxoSmithKline, Hanmi, Intarcia Therapeu-
tics, Janssen, Lexicon, MannKind Corp., Merck
Sharp & Dohme, Novo Nordisk, Pfizer, Sanofi,
and Takeda. S.E.K. is a consultant/advisory board
member for Boehringer Ingelheim, Elcelyx, Eli Lilly
and Co., GlaxoSmithKline, Intarcia Therapeutics,
Janssen, Merck Sharp & Dohme, Novo Nordisk,
and Receptos and has received grant support
from Eli Lilly and Co. No other potential conflicts
of interest relevant to this article were reported.
References
1. International Diabetes Federation. IDF Dia-
betes Atlas. 7th ed. Available from www
.diabetesatlas.org. Accessed 31 December 2015
2. Centers for Disease Control and Prevention.
National Diabetes Statistics Report: Estimates
of Diabetes and Its Burden in the United States,
2014. Atlanta, GA, U.S. Department of Health
and Human Services, 2014
3. Seuring T, Archangelidi O, SuhrckeM. The eco-
nomic costs of type 2diabetes: a global systematic
review. Pharmacoeconomics 2015;33:811–831
4. World Health Organization. Global Health
Risks: Mortality and Burden of Disease Attribut-
able to Selected Major Risks. Geneva, Switzer-
land, World Health Organization, 2009
5. Pan XR, Li GW, Hu YH, et al. Effects of diet
and exercise in preventing NIDDM in people with
impaired glucose tolerance. The Da Qing IGT
and Diabetes Study. Diabetes Care 1997;20:
537–544
6. Tuomilehto J, Lindstro¨m J, Eriksson JG, et al.;
Finnish Diabetes Prevention Study Group. Pre-
vention of type 2 diabetes mellitus by changes
in lifestyle among subjects with impaired glucose
tolerance. N Engl J Med 2001;344:1343–1350
7. Knowler WC, Barrett-Connor E, Fowler SE,
et al.; Diabetes Prevention Program Research
Group. Reduction in the incidence of type 2
diabetes with lifestyle intervention or metfor-
min. N Engl J Med 2002;346:393–403
8. Ramachandran A, Snehalatha C, Mary S,
Mukesh B, Bhaskar AD, Vijay V; Indian Diabetes
Prevention Programme. The Indian Diabetes
Prevention Programme shows that lifestyle
modification and metformin prevention type 2
diabetes in Asian Indian subjects with impaired
glucose tolerance (IDPP-1). Diabetologia 2006;
49:289–297
9. Ramachandran A, Snehalatha C,Mary S, et al.
Pioglitazone does not enhance the effectiveness
of lifestyle modification in preventing conver-
sion of impaired glucose tolerance to diabetes
in Asian Indians: results of the Indian Diabetes Pre-
vention Programme-2 (IDPP-2). Diabetologia 2009;
52:1019–1026
10. DeFronzo RA, Tripathy D, Schwenke DC,
et al.; ACT NOWStudy. Pioglitazone for diabetes
prevention in impaired glucose tolerance. N
Engl J Med 2011;364:1104–1115
11. Saito T, Watanabe M, Nishida J, et al.; Zen-
sharen Study for Prevention of Lifestyle Diseases
Group. Lifestyle modification and prevention of
type 2 diabetes in overweight Japanese with
impaired fasting glucose levels: a randomized
controlled trial. Arch Intern Med 2011;171:
1352–1360
12. Kosaka K, Noda M, Kuzuya T. Prevention of
type 2 diabetes by lifestyle intervention: a Jap-
anese trial in IGT males. Diabetes Res Clin Pract
2005;67:152–162
13. Buchanan TA, Xiang AH, Peters RK, et al.
Preservation of pancreatic b-cell function and
prevention of type 2 diabetes by pharmacolog-
ical treatment of insulin resistance in high-risk
hispanic women. Diabetes 2002;51:2796–2803
14. Gerstein HC, Yusuf S, Bosch J, et al.; DREAM
(Diabetes REduction Assessment with ramipril
and rosiglitazone Medication) Trial Investiga-
tors. Effect of rosiglitazone on the frequency
of diabetes in patients with impaired glucose
tolerance or impaired fasting glucose: a rando-
mised controlled trial. Lancet 2006;368:1096–
1105
15. Zinman B, Harris SB, Neuman J, et al. Low-
dose combination therapy with rosiglitazone
and metformin to prevent type 2 diabetes mel-
litus (CANOE trial): a double-blind randomised
controlled study. Lancet 2010;376:103–111
16. Gerstein HC, Bosch J, Dagenais GR, et al.;
ORIGIN Trial Investigators. Basal insulin and car-
diovascular and other outcomes in dysglycemia.
N Engl J Med 2012;367:319–328
17. Chiasson J-L, Josse RG, Gomis R, Hanefeld
M, Karasik A, Laakso M; STOP-NIDDM Trial Re-
search Group. Acarbose for prevention of type 2
diabetesmellitus: the STOP-NIDDM randomised
trial. Lancet 2002;359:2072–2077
18. Kawamori R, Tajima N, Iwamoto Y, Kashiwagi
A, Shimamoto K, Kaku K; Voglibose Ph-3 Study
Group. Voglibose for prevention of type 2 diabe-
tes mellitus: a randomised, double-blind trial
in Japanese individuals with impaired glucose
tolerance. Lancet 2009;373:1607–1614
19. Holman RR, North BV, Tunbridge FK. Possi-
ble prevention of type 2 diabetes with acarbose
or metformin. Diabetes 2000;49(Suppl. 1):
A111
20. Holman RR, Haffner SM, McMurray JJ,
et al.; NAVIGATOR Study Group. Effect of
nateglinide on the incidence of diabetes and
1198 Diabetes Prevention Update and Future Directions Diabetes Care Volume 39, July 2016
cardiovascular events. N Engl J Med 2010;362:
1463–1476
21. Torgerson JS, Hauptman J, Boldrin MN,
Sjo¨stro¨m L. XENical in the Prevention of Diabe-
tes in Obese Subjects (XENDOS) study: a ran-
domized study of orlistat as an adjunct to
lifestyle changes for the prevention of type 2
diabetes in obese patients. Diabetes Care
2004;27:155–161
22. Pi-Sunyer X, Astrup A, Fujioka K, et al.;
SCALE Obesity and Prediabetes NN8022-1839
Study Group. A randomized, controlled trial of
3.0 mg of liraglutide in weight management. N
Engl J Med 2015;373:11–22
23. Albright AL, Gregg EW. Preventing type 2
diabetes in communities across the U.S.: the
National Diabetes Prevention Program. Am J
Prev Med 2013;44(Suppl. 4):S346–S351
24. U.S. Department of Health and Human Ser-
vice. Independent experts confirm that diabetes
prevention model supported by the Affordable
Care Act saves money and improves health [In-




.html. Accessed 4 April 2016
25. Fradkin JE, Roberts BT, Rodgers GP. What’s
preventing us from preventing type 2 diabetes?
N Engl J Med 2012;367:1177–1179
26. Kahn R, Davidson MB. The reality of type 2
diabetes prevention. Diabetes Care 2014;37:
943–949
27. Li G, Zhang P, Wang J, et al. The long-term
effect of lifestyle interventions to prevent dia-
betes in the China Da Qing Diabetes Prevention
Study: a 20-year follow-up study. Lancet 2008;
371:1783–1789
28. Li G, Zhang P, Wang J, et al. Cardiovascular
mortality, all-cause mortality, and diabetes in-
cidence after lifestyle intervention for people
with impaired glucose tolerance in the Da
Qing Diabetes Prevention Study: a 23-year fol-
low-up study. Lancet Diabetes Endocrinol 2014;
2:474–480
29. Gong Q, Gregg EW,Wang J, et al. Long-term
effects of a randomised trial of a 6-year lifestyle
intervention in impaired glucose tolerance on
diabetes-related microvascular complications:
the China Da Qing Diabetes Prevention Out-
come Study. Diabetologia 2011;54:300–307
30. Lindstro¨m J, Louheranta A, Mannelin M,
et al.; Finnish Diabetes Prevention Study Group.
The Finnish Diabetes Prevention Study (DPS):
lifestyle intervention and 3-year results on diet
and physical activity. Diabetes Care 2003;26:
3230–3236
31. Lindstro¨m J, Ilanne-Parikka P, Peltonen M,
et al.; Finnish Diabetes Prevention Study Group.
Sustained reduction in the incidence of type 2
diabetes by lifestyle intervention: follow-up of
the Finnish Diabetes Prevention Study. Lancet
2006;368:1673–1679
32. Lindstro¨m J, Peltonen M, Eriksson JG, et al.;
Finnish Diabetes Prevention Study (DPS). Im-
proved lifestyle and decreased diabetes risk
over 13 years: long-term follow-up of the rand-
omised Finnish Diabetes Prevention Study
(DPS). Diabetologia 2013;56:284–293
33. Knowler WC, Hamman RF, Edelstein SL,
et al.; Diabetes Prevention Program Research
Group. Prevention of type 2 diabetes with
troglitazone in the Diabetes Prevention Pro-
gram. Diabetes 2005;54:1150–1156
34. Knowler WC, Fowler SE, Hamman RF, et al.;
Diabetes Prevention Program Research Group.
10-year follow-up of diabetes incidence and
weight loss in the Diabetes Prevention Program
Outcomes Study. Lancet 2009;374:1677–1686
35. Diabetes Prevention Program Research
Group. Long-term effects of lifestyle interven-
tion or metformin on diabetes development
and microvascular complications over 15-year
follow-up: the Diabetes Prevention Program
Outcomes Study. Lancet Diabetes Endocrinol
2015;3:866–875
36. Herman WH, Hoerger TJ, Brandle M, et al.;
Diabetes Prevention Program Research Group.
The cost-effectiveness of lifestyle modification
or metformin in preventing type 2 diabetes in
adults with impaired glucose tolerance. Ann In-
tern Med 2005;142:323–332
37. Snehalatha C, Mary S, Joshi VV,
Ramachandran A. Beneficial effects of strategies
for primary prevention of diabetes on cardio-
vascular risk factors: results of the Indian Dia-
betes Prevention Programme. Diab Vasc Dis Res
2008;5:25–29
38. Gerstein HC, Mohan V, Avezum A, et al.;
DREAM On (Diabetes Reduction Assessment
with Ramipril and Rosiglitazone Medication On-
going Follow-up) Investigators. Long-term ef-
fect of rosiglitazone and/or ramipril on the
incidence of diabetes. Diabetologia 2011;54:
487–495
39. DeFronzo RA, Abdul-Ghani M. Type 2 dia-
betes can be prevented with early pharmacolog-
ical intervention. Diabetes Care 2011;34(Suppl. 2):
S202–S209
40. Gerstein H, Yusuf S, Riddle MC, Ryden L,
Bosch J; ORIGIN Trial Investigators. Rationale,
design, and baseline characteristics for a large
international trial of cardiovascular disease pre-
vention in people with dysglycemia: the ORIGIN
Trial (Outcome Reduction with an Initial Glar-
gine Intervention). Am Heart J 2008;155:26–
32, 32.e1–32.e6
41. ORIGIN Trial Investigators. Cardiovascular
and other outcomes postinterventionwith insulin
glargine and omega-3 fatty acids (ORIGINALE).
Diabetes Care 2016;39:709–716
42. Holman RR, Blackwell L, Stratton IM,
Manley SE, Tucker L, Frighi V. Six-year results
from the Early Diabetes Intervention Trial. Dia-
bet Med 2003;20(Suppl. 2):15
43. Taba´k AG, Herder C, Rathmann W, Brunner
EJ, Kivima¨ki M. Prediabetes: a high-risk state for
diabetes development. Lancet 2012;379:2279–
2290
44. Abdul-Ghani MA, Tripathy D, DeFronzo RA.
Contributions of b-cell dysfunction and insulin
resistance to the pathogenesis of impaired glu-
cose tolerance and impaired fasting glucose. Di-
abetes Care 2006;29:1130–1139
45. American Diabetes Association. Classifica-
tion and diagnosis of diabetes. Sec. 2. In Stan-
dards of Medical Care in Diabetesd2016.
Diabetes Care 2016;39(Suppl. 1):S13–S22
46. National Diabetes Data Group. Classifica-
tion and diagnosis of diabetes mellitus and
other categories of glucose intolerance. Diabe-
tes 1979;28:1039–1057
47. Expert Committee on the Diagnosis and
Classification of Diabetes Mellitus. Report of
the Expert Committee on the Diagnosis and
Classification of Diabetes Mellitus. Diabetes
Care 1997;20:1183–1197
48. Genuth S, Alberti KG, Bennett P, et al.; Ex-
pert Committee on the Diagnosis and Classifica-
tion of Diabetes Mellitus. Follow-up report on
the diagnosis of diabetes mellitus. Diabetes
Care 2003;26:3160–3167
49. World Health Organization. Definition and
Diagnosis of DiabetesMellitus and Intermediate
Hyperglycemia: Report of a WHO/IDF Consulta-
tion. Geneva, Switzerland, World Health Orga-
nization, 2006
50. International Expert Committee. Interna-
tional Expert Committee report on the role of
the A1C assay in the diagnosis of diabetes. Di-
abetes Care 2009;32:1327–1334
51. World Health Organization. Use of Glycated
Haemoglobin (HbA1c) in the Diagnosis of Diabe-
tes Mellitus: Abbreviated Report of a WHO Con-
sultation. Geneva, Switzerland, World Health
Organization, 2011
52. World Health Organization. Definition, Di-
agnosis and Classification of Diabetes Mellitus
and Its Complications: Report of a WHO Consul-
tation. Part 1. Diagnosis and Classification of
Diabetes Mellitus. Geneva, Switzerland, World
Health Organization, 1999
53. National Institute for Health and Clinical
Excellence. Preventing Type 2 Diabetes: Risk
Identification and Interventions for Individuals
at High Risk. NICE Public Health Guidance 38.
Manchester, U.K., National Institute for Health
and Clinical Excellence, 2012
54. Morris DH, Khunti K, Achana F, et al. Pro-
gression rates from HbA1c 6.0-6.4% and other
prediabetes definitions to type 2 diabetes: a
meta-analysis. Diabetologia 2013;56:1489–
1493
55. James C, Bullard KM, Rolka DB, et al. Impli-
cations of alternative definitions of prediabetes
for prevalence in U.S. adults. Diabetes Care
2011;34:387–391
56. Plantinga LC, Crews DC, Coresh J, et al.; CDC
CKD Surveillance Team. Prevalence of chronic
kidney disease in US adults with undiagnosed
diabetes or prediabetes. Clin J Am Soc Nephrol
2010;5:673–682
57. Tesfaye S, Boulton AJ, Dyck PJ, et al.; Tor-
onto Diabetic Neuropathy Expert Group. Dia-
betic neuropathies: update on definitions,
diagnostic criteria, estimation of severity, and
treatments. Diabetes Care 2010;33:2285–2293
58. Wu JS, Yang YC, Lin TS, et al. Epidemiolog-
ical evidence of altered cardiac autonomic func-
tion in subjects with impaired glucose tolerance
but not isolated impaired fasting glucose. J Clin
Endocrinol Metab 2007;92:3885–3889
59. Schroeder EB, Chambless LE, Liao D, et al.;
Atherosclerosis Risk in Communities (ARIC)
study. Diabetes, glucose, insulin, and heart
rate variability: the Atherosclerosis Risk in Com-
munities (ARIC) study. Diabetes Care 2005;28:
668–674
60. Gerstein HC, Santaguida P, Raina P, et al.
Annual incidence and relative risk of diabetes
in people with various categories of dysglyce-
mia: a systematic overview andmeta-analysis of
prospective studies. Diabetes Res Clin Pract
2007;78:305–312
61. Forouhi NG, Luan J, Hennings S, Wareham
NJ. Incidence of type 2 diabetes in England and
care.diabetesjournals.org Cefalu and Associates 1199
its association with baseline impaired fasting
glucose: the Ely study 1990-2000. Diabet Med
2007;24:200–207
62. Anjana RM, Shanthi Rani CS, DeepaM, et al.
Incidence of diabetes and prediabetes and pre-
dictors of progression among Asian Indians:
10-year follow-up of the Chennai Urban Rural
Epidemiology Study (CURES). Diabetes Care
2015;38:1441–1448
63. Tirosh A, Shai I, Tekes-Manova D, et al.;
Israeli Diabetes Research Group. Normal fasting
plasma glucose levels and type 2 diabetes in
young men. N Engl J Med 2005;353:1454–1462
64. Yeboah J, Bertoni AG, Herrington DM, Post
WS, Burke GL. Impaired fasting glucose and the
risk of incident diabetes mellitus and cardio-
vascular events in an adult population: MESA
(Multi-Ethnic Study of Atherosclerosis). J Am
Coll Cardiol 2011;58:140–146
65. Seshasai SR, Kaptoge S, Thompson A, et al.;
Emerging Risk Factors Collaboration. Diabetes
mellitus, fasting glucose, and risk of cause-
specific death. N Engl J Med 2011;364:829–841
66. Xu T, Liu W, Cai X, et al. Risk of coronary
heart disease in different criterion of impaired
fasting glucose: ameta-analysis. Medicine 2015;
94:e1740
67. Ning F, Zhang L, Dekker JM, et al.; DECODE
Finnish and Swedish Study Investigators. Devel-
opment of coronary heart disease and ischemic
stroke in relation to fasting and 2-hour plasma
glucose levels in the normal range. Cardiovasc
Diabetol 2012;11:76
68. Jackson SL, Long Q, Rhee MK, et al. Weight
loss and incidence of diabetes with the Veterans
Health Administration MOVE! lifestyle change
programme: an observational study. Lancet Di-
abetes Endocrinol 2015;3:173–180
69. MauMK, Keawe’aimoku Kaholokula J, West
MR, et al. Translating diabetes prevention into
native Hawaiian and Pacific Islander communi-
ties: the PILI ’Ohana Pilot project. Prog Commu-
nity Health Partnersh 2010;4:7–16
70. Pagoto SL, Kantor L, Bodenlos JS, GitkindM,
Ma Y. Translating the diabetes prevention pro-
gram into a hospital-based weight loss program.
Health Psychol 2008;27(Suppl.):S91–S98
71. Seidel MC, Powell RO, Zgibor JC, Siminerio
LM, Piatt GA. Translating the Diabetes Preven-
tion Program into an urban medically under-
served community: a nonrandomized prospective
intervention study. Diabetes Care 2008;31:684–
689
72. Boltri JM, Davis-Smith YM, Seale JP,
Shellenberger S, Okosun IS, Cornelius ME. Dia-
betes prevention in a faith-based setting: re-
sults of translational research. J Public Health
Manag Pract 2008;14:29–32
73. Aldana SG, Barlow M, Smith R, et al. The
Diabetes Prevention Program: a worksite expe-
rience. AAOHN J 2005;53:499–505; quiz 506–
507
74. Whittemore R, Melkus G, Wagner J, Dziura
J, Northrup V, Grey M. Translating the Diabetes
Prevention Program to primary care: a pilot
study. Nurs Res 2009;58:2–12
75. Block G, Azar KM, Romanelli RJ, et al. Di-
abetes prevention and weight loss with a fully
automated behavioral intervention by email,
web, and mobile phone: a randomized con-
trolled trial among persons with prediabetes.
J Med Internet Res 2015;17:e240
76. Ramachandran A, Snehalatha C, Ram J,
et al. Effectiveness of mobile phone messaging
in prevention of type 2 diabetes by lifestyle
modification in men in India: a prospective,
parallel-group, randomised controlled trial. Lan-
cet Diabetes Endocrinol 2013;1:191–198
77. Saaristo T, Peltonen M, Keina¨nen-
Kiukaanniemi S, et al.; FIN-D2D Study Group.
National type 2 diabetes prevention programme
in Finland: FIN-D2D. Int J Circumpolar Health
2007;66:101–112
78. Dunbar JA, Jayawardena A, Johnson G, et al.
Scaling up diabetes prevention in Victoria, Aus-
tralia: policy development, implementation,
and evaluation. Diabetes Care 2014;37:934–942
79. Sakane N, Sato J, Tsushita K, et al.; Japan
Diabetes Prevention Program (JDPP) Research
Group. Prevention of type 2 diabetes in a pri-
mary healthcare setting: three-year results of
lifestyle intervention in Japanese subjects with
impaired glucose tolerance. BMC Public Health
2011;11:40
80. Wareham NJ. Mind the gap: efficacy versus
effectiveness of lifestyle interventions to pre-
vent diabetes. Lancet Diabetes Endocrinol
2015;3:160–161
81. Li G, Hu Y, Yang W, et al.; DA Qing IGT and
Diabetes Study. Effects of insulin resistance and
insulin secretion on the efficacy of interventions
to retard development of type 2 diabetes melli-
tus: the DA Qing IGT and Diabetes Study. Dia-
betes Res Clin Pract 2002;58:193–200
82. Lindstro¨m J, Tuomilehto J. The diabetes risk
score: a practical tool to predict type 2 diabetes
risk. Diabetes Care 2003;26:725–731
83. Lindstro¨m J, Peltonen M, Eriksson JG, et al.;
Finnish Diabetes Prevention Study (DPS) Group.
Determinants for the effectiveness of lifestyle
intervention in the Finnish Diabetes Prevention
Study. Diabetes Care 2008;31:857–862
84. de Mello VDF, Lindstro¨m J, Eriksson J, et al.
Insulin secretion and its determinants in the
progression of impaired glucose tolerance to
type 2 diabetes in impaired glucose-tolerant in-
dividuals: the Finnish Diabetes Prevention
Study. Diabetes Care 2012;35:211–217
85. Tuomilehto H, Peltonen M, Partinen M,
et al.; Finnish Diabetes Prevention Study Group.
Sleep duration, lifestyle intervention, and inci-
dence of type 2 diabetes in impaired glucose
tolerance: The Finnish Diabetes Prevention
Study. Diabetes Care 2009;32:1965–1971
86. Wang J, Kuusisto J, Va¨nttinen M, et al. Var-
iants of transcription factor 7-like 2 (TCF7L2)
gene predict conversion to type 2 diabetes in
the Finnish Diabetes Prevention Study and are
associated with impaired glucose regulation
and impaired insulin secretion. Diabetologia
2007;50:1192–1200
87. Siitonen N, Lindstro¨m J, Eriksson J, et al.
Association between a deletion/insertion poly-
morphism in the a2B-adrenergic receptor gene
and insulin secretion and type 2 diabetes. The
Finnish Diabetes Prevention Study. Diabetolo-
gia 2004;47:1416–1424
88. Laaksonen DE, Siitonen N, Lindstro¨m J,
et al.; Finnish Diabetes Prevention Study Group.
Physical activity, diet, and incident diabetes in
relation to an ADRA2B polymorphism. Med Sci
Sports Exerc 2007;39:227–232
89. Uusitupa MI, Stanca´kova´ A, Peltonen M,
et al. Impact of positive family history and
genetic risk variants on the incidence of diabe-
tes: the Finnish Diabetes Prevention Study. Di-
abetes Care 2011;34:418–423
90. Kitabchi AE, Temprosa M, Knowler WC,
et al.; Diabetes Prevention Program Research
Group. Role of insulin secretion and sensitivity
in the evolution of type 2 diabetes in the diabe-
tes prevention program: effects of lifestyle in-
tervention and metformin. Diabetes 2005;54:
2404–2414
91. Aroda VR, Christophi CA, Edelstein SL, et al.;
Diabetes Prevention Program Research Group.
The effect of lifestyle intervention and metfor-
min on preventing or delaying diabetes among
women with and without gestational diabetes:
the Diabetes Prevention Program outcomes
study 10-year follow-up. J Clin Endocrinol
Metab 2015;100:1646–1653
92. Florez JC, Jablonski KA, Bayley N, et al.; Di-
abetes Prevention Program Research Group.
TCF7L2 polymorphisms and progression to di-
abetes in the Diabetes Prevention Program.
N Engl J Med 2006;355:241–250
93. Dabelea D, Ma Y, Knowler WC, et al.; Dia-
betes Prevention Program Research Group.
Diabetes autoantibodies do not predict pro-
gression to diabetes in adults: the Diabetes
Prevention Program. Diabet Med 2014;31:
1064–1068
94. Perreault L, Pan Q, Mather KJ, Watson KE,
Hamman RF, Kahn SE; Diabetes Prevention Pro-
gram Research Group. Regression from pre-
diabetes to normal glucose regulation is
associated with long-term reduction in diabetes
risk: results from the Diabetes Prevention Pro-
gram Outcomes Study. Lancet 2012;379:2243–
2251
95. Ramachandran A, Snehalatha C, Samith
Shetty A, Nanditha A. Predictive value of
HbA1c for incident diabetes among subjects
with impaired glucose tolerance–analysis of
the Indian Diabetes Prevention Programmes.
Diabet Med 2012;29:94–98
96. Nanditha A, Ram J, Snehalatha C, et al. Early
improvement predicts reduced risk of incident
diabetes and improved cardiovascular risk in
prediabetic Asian Indian men participating in a
2-year lifestyle intervention program. Diabetes
Care 2014;37:3009–3015
97. Ram J, Snehalatha C, Selvam S, et al. The
oral disposition index is a strong predictor of
incident diabetes in Asian Indian prediabetic
men. Acta Diabetol 2015;52:733–741
98. Siu AL; U S Preventive Services Task Force.
Screening for abnormal blood glucose and
type 2 diabetes mellitus: U.S. Preventive Ser-
vices Task Force recommendation statement.
Ann Intern Med 2015;163:861–868
99. Congress.gov. H.R.2102: Medicare Diabe-
tes Prevention Act of 2015 [Internet]. Available
from https://www.congress.gov/bill/114th-
congress/house-bill/2102. Accessed 6 Novem-
ber 2015
100. Patient-Centered Outcomes Research In-
stitute. Future Research Prioritization: Compar-
ative Effectiveness of Strategies for Diabetes
Prevention and Prediabetes [Internet], July





1200 Diabetes Prevention Update and Future Directions Diabetes Care Volume 39, July 2016
101. Ackermann RT, Kenrik Duru O, Albu JB,
et al.; NEXT-D Study Group. Evaluating diabetes
health policies using natural experiments: the
natural experiments for translation in diabetes
study. Am J Prev Med 2015;48:747–754
102. Thorpe KE. Analysis & commentary: the
Affordable Care Act lays the groundwork for a
national diabetes prevention and treatment
strategy. Health Aff (Millwood) 2012;31:61–66
103. Community Preventive Services Task
Force. Diabetes prevention and control: com-
bined diet and physical activity promotion pro-
grams to prevent type 2 diabetes among people
at increased risk: task force finding and ratio-
nale statement [Internet]. Available from
http://www.thecommunityguide.org/diabetes/
supportingmaterials/RRcombineddietandpa
.html. Accessed 6 November 2015
104. Phung OJ, Sood NA, Sill BE, Coleman CI.
Oral anti-diabetic drugs for the prevention of
Type 2 diabetes. Diabet Med 2011;28:948–964
105. DeFronzo RA, Abdul-Ghani MA. Preserva-
tion of b-cell function: the key to diabetes pre-
vention. J Clin Endocrinol Metab 2011;96:2354–
2366
106. Nissen SE, Wolski K. Rosiglitazone revis-
ited: an updated meta-analysis of risk for myo-
cardial infarction and cardiovascular mortality.
Arch Intern Med 2010;170:1191–1201
107. Astrup A, Carraro R, Finer N, et al.
NN8022-1807 Investigators. Safety, tolerability,
and sustained weight loss over 2 years with the
once-daily human GLP-1 analog, liraglutide. Int
J Obes 2012;36:843–854
108. RISE Consortium. Restoring Insulin Secre-
tion (RISE): design of studies of b-cell preserva-
tion in prediabetes and early type 2 diabetes
across the life span. Diabetes Care 2014;37:
780–788
109. Diabetes Prevention Program Research
Group. Long-term safety, tolerability, and
weight loss associated with metformin in the
Diabetes Prevention Program Outcomes Study.
Diabetes Care 2012;35:731–737
110. Diabetes Prevention Program Research
Group. The 10-year cost-effectiveness of life-
style intervention or metformin for diabetes
prevention: an intent-to-treat analysis of the
DPP/DPPOS. Diabetes Care 2012;35:723–730
111. Ratner RE, Christophi CA, Metzger BE,
et al.; Diabetes Prevention Program Research
Group. Prevention of diabetes in women
with a history of gestational diabetes: effects
of metformin and lifestyle interventions. J Clin
Endocrinol Metab 2008;93:4774–4779
112. Sussman JB, Kent DM, Nelson JP, Hayward
RA. Improving diabetes prevention with benefit
based tailored treatment: risk based reanalysis
of Diabetes Prevention Program. BMJ 2015;350:
h454
113. American Diabetes Association. Preven-
tion or delay of type 2 diabetes. Sec. 4. In Stan-
dards of Medical Care in Diabetesd2016.
Diabetes Care 2016;39(Suppl. 1):S36–S38
114. Moin T, Li J, Duru OK, et al. Metformin
prescription for insured adults with prediabetes
from 2010 to 2012: a retrospective cohort
study. Ann Intern Med 2015;162:542–548
115. Hanefeld M, Schaper F. Acarbose: oral anti-
diabetes drug with additional cardiovascular ben-
efits. Expert Rev Cardiovasc Ther 2008;6:153–163
116. U.S. Food and Drug Administration. Guid-
ance for Industry: Diabetes Mellitus: Developing
Drugs and Therapeutic Biologics for Treatment
and Prevention [Draft Guidance] [Internet], Feb-
ruary 2008. Available from http://www.fda
.gov/downloads/Drugs/GuidanceCompliance
RegulatoryInformation/Guidances/UCM071624
.pdf. Accessed 12 November 2015
117. Gerstein HC. Point: If it is important to
prevent type 2 diabetes, it is important to con-
sider all proven therapies within a comprehen-
sive approach. Diabetes Care 2007;30:432–434
118. Palmer JP, Fleming GA, Greenbaum CJ,
et al. C-peptide is the appropriate outcome
measure for type 1 diabetes clinical trials to pre-
serve b-cell function: report of an ADA work-
shop, 21-22 October 2001. Diabetes 2004;53:
250–264
119. U.S. Food and Drug Administration. FDA ap-
proves new indication for Crestor [Internet].Avail-
able from http://www.fda.gov/NewsEvents/
Newsroom/PressAnnouncements/ucm200128.htm.
Accessed 17 February 2016
120. Aroda VR, Edelstein SL, Goldberg RB, et al.;
Diabetes Prevention Program Research Group.
Long-term metformin use and vitamin B12 de-
ficiency in the Diabetes Prevention Program
Outcomes Study. J Clin Endocrinol Metab
2016;101:1754–1761
121. Alssema M, Vistisen D, Heymans MW,
et al.; DETECT-2 collaboration. The Evaluation
of Screening and Early Detection Strategies for
Type 2 Diabetes and Impaired Glucose Toler-
ance (DETECT-2) update of the Finnish diabetes
risk score for prediction of incident type 2 di-
abetes. Diabetologia 2011;54:1004–1012
122. American Diabetes Association. Type 2 di-
abetes risk test [Internet]. Available from http://
www.diabetes.org/are-you-at-risk/diabetes-risk-
test/?loc=atrisk-slabnav. Accessed 17 January
2016
123. DiabetesUK.Diabetes risk score assessment
tool [Internet]. Available from https://www
.diabetes.org.uk/professionals/diabetes-risk-
score-assessment-tool. Accessed 17 January 2016
124. Chen L, Magliano DJ, Balkau B, et al.
AUSDRISK: an Australian type 2 diabetes risk as-
sessment tool based on demographic, lifestyle
and simple anthropometric measures. Med J
Aust 2010;192:197–202
125. Mohan V, Deepa R, DeepaM, Somannavar
S, Datta M. A simplified Indian diabetes risk
score for screening for undiagnosed diabetic
subjects. J Assoc Physicians India 2005;53:759–
763
126. Jiang L, Manson SM, Beals J, et al.; Special
Diabetes Program for Indians Diabetes Preven-
tion Demonstration Project. Translating the Di-
abetes Prevention Program into American
Indian and Alaska Native communities: results
from the Special Diabetes Program for Indians
Diabetes Prevention demonstration project. Di-
abetes Care 2013;36:2027–2034
127. Ackermann RT, Finch EA, Brizendine E,
Zhou H, Marrero DG. Translating the Diabetes
Prevention Program into the community: the
DEPLOYpilot study. Am J PrevMed 2008;35:357–363
128. Lipscomb ER, Finch EA, Brizendine E, Saha
CK, Hays LM, Ackermann RT. Reduced 10-year
risk of coronary heart disease in patients who
participated in a community-based diabetes
prevention program: the DEPLOY pilot study.
Diabetes Care 2009;32:394–396
129. YMCA. Measureable progress, unlimited
support: Diabetes Prevention Program fact sheet
[Internet], December 2015. Available from http://
www.ymca.net/diabetes-prevention/statistics
.html. Accessed 21 December 2015
130. Prasad VM. Using mobile technology for
health [Internet]. Available from http://www
.searo.who.int/entity/noncommunicable_diseases/
events/ncd-bengaluru-mobile-technology-
for-health.pdf. Accessed 17 December 2015
131. Finnish Diabetes Association. Implementa-
tion of type 2 diabetes prevention plan: project
plan 2003–2007, FIN-D2D project [Internet]. Avail-
able from http://www.diabetes.fi/files/1107/
Implementation_of_Type_2_Diabetes_Prevention._
Project_Plan_2003-2007.pdf. Accessed 18 De-
cember 2015
132. Saaristo T, Moilanen L, Korpi-Hyo¨va¨lti E,
et al. Lifestyle intervention for prevention of
type 2 diabetes in primary health care: one-
year follow-up of the Finnish National Diabetes
Prevention Program (FIN-D2D). Diabetes Care
2010;33:2146–2151
133. Schwarz PE, Lindstro¨m J, Kissimova-
Scarbeck K, et al.; DE-PLAN project. The Euro-
pean perspective of type 2 diabetes prevention:
diabetes in Europe–prevention using lifestyle,
physical activity and nutritional intervention
(DE-PLAN) project. Exp Clin Endocrinol Diabetes
2008;116:167–172
134. Lindstro¨m J, Neumann A, Sheppard KE,
et al. Take action to prevent diabetes–the
IMAGE toolkit for the prevention of type 2
diabetes in Europe. Horm Metab Res 2010;
42(Suppl. 1):S37–S55
135. Nanditha A, Ma RCW, Ramachandran A,
et al. Diabetes in Asia and the Pacific: implica-
tions for the global epidemic. Diabetes Care
2016;39:472–485
136. Singapore Health Promotion Board. Pre-
diabetes intervention programme [Internet]. Avail-
able from http://www.hpb.gov.sg/HOPPortal/
programmes-article/5844. Accessed 18 Decem-
ber 2015
137. Singapore Health Promotion Board.




138. Singapore Health Promotion Board.Work-
place health promotion [Internet]. Available
from http://www.hpb.gov.sg/HOPPortal/
programmes-article/5568. Accessed 3 March
2016
139. Neudorfer Y. Impact investing in Israel.
Presentation to the G8 Impact Investment Task-
force. 9 July 2015 [Internet]. Available from
http://www.socialimpactinvestment.org/reports/
Impact-Investment-in-Israel-Yaron-Neudorfer.pptx.
Accessed 3 March 2016
care.diabetesjournals.org Cefalu and Associates 1201
